



**e-TENDER NO:- BPPI/DRUG-050/2017**

**TENDER FOR SUPPLY OF DRUGS**

**TO**

**Bureau of Pharma Public Sector Undertakings of  
India (BPPI)**

**For the year 2017-19**



**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA**

(Set up under the Department of Pharmaceuticals, Govt. of India)

IDPL corporate office Complex, Old Delhi-Gurgaon Road, Dundahera, Gurgaon 122016

Telephone: 0124-4040759 / 4556751; Fax: 0124-2340370 Website: [janaushadhi.gov.in](http://janaushadhi.gov.in)

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA**  
**(BPPI)**

(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003

Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)

Telephone: **0124-4556751**; Fax: **0124-2340370** Website: [janaushadhi.gov.in](http://janaushadhi.gov.in)

**ONLINE TENDER FOR THE SUPPLY OF DRUGS TO BUREAU OF PHARMA PSU OF INDIA FOR THE YEAR 2017-2019**

Tender Reference		<b>BPPI/DRUG-050/2017 Dt. 22/05/2017</b>
Date of availability of tender documents on website		<b>22/05/2017 (Monday)</b>
Time and date and place pre-bid meeting		<b>11:00 AM on 30/05/2017(Tuesday)</b>  Bureau of Pharma PSUs of India, IDPL corporate office, IDPL Complex, Old Delhi-Gurgaon Road, Dundaheera, Gurgaon-122016 (Haryana)
Last date and time for submission of Online Bid i.e. Bid Submission End Date and time		<b>13/06/2017 upto 11:00 A.M.</b>
<b>Last Date for submission of EMD in physical Form in office of Bureau of Pharma PSUs of India, IDPL corporate office Complex, Old Delhi-Gurgaon Road, Dundaheera, Gurgaon- 122016 (Haryana)</b>		<b>14/06/2017</b>
Time and date of opening of Technical Bid		<b>11:30 AM on 14/06/2017 (Wednesday)</b>

Place of opening of tender	Bureau of Pharma PSUs of India, IDPL corporate office Complex, Old Delhi-Gurgaon Road, Dundahera, Gurgaon- 122016 (Haryana)
Address for Communication	Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office Complex, Old Delhi-Gurgaon Road, Dundahera, Gurgaon- 122016 (Haryana)
Cost of the Tender Document	<b>Free of cost</b>
Contact Person for clarification if any	<p>1. Sh. Mahadev Agarwal, Manager (Procurement) Phone:- 0124-4040756 Mob:- 9811780789 Email: mahadevpharm.bppi@gmail.com</p> <p>2. Mr. Sandeep Sapan Patra, Sr. Executive (Procurement) Phone:- 0124-4556767 Mob:- 9090512532 Email:- proc5.bppi@gmail.com</p> <p>3. Mr. Rupak Kumar, Executive (Procurement) Phone:- 0124-4556764/767 Mob:- 7291087675 Email:- proc3.bppi@gmail.com</p>

*The tender document can be downloaded free of cost from the CPPP e-Procurement Portal <https://eprocure.gov.in> and from the website of BPPI: [janaushadhi.gov.in](http://janaushadhi.gov.in).*

## TABLE OF CONTENTS

<b>Sl.No.</b>	<b>Description</b>	<b>Page No.</b>
1.	Last Date and time for submission of ONLINE Tender	7
2.	Eligibility Criteria	7
3.	General Conditions	8
4.	Technical Bid – Cover “A”	10
5.	Price Bid – Cover “B”	13
6.	Opening of Cover “A” and Cover “B” of Tender	14
7.	Earnest Money Deposit	15
8.	Other Conditions	16
9.	Acceptance of Tender	18
10.	Security Deposit and Agreement	19
11.	Methodology for placing orders	20
12.	Supply Conditions	22
13.	Logograms	24
14.	Packing	24
15.	Quality Testing	25
16.	Payment Provisions	26
17.	Handling & Testing Charges	28
18.	Liquidated Damages and other penalties	28
19.	Deduction and other penalties on account of Quality failure	28
20.	Blacklisting in the event of withdrawal from the tender, and Non-Adherence to the Quality Standards and supply schedule	30
21.	Saving Clause	32
22.	Resolution of Disputes	32
23.	Appeal	32
24.	Contacting the Purchaser by the Bidder	32
25.	Fraudulent and Corrupt Practices	33
26.	Jurisdiction	35
27.	ANNEXURE-I (BARCODE REQUIREMENTS)	36

28.	ANNEXURE-II ( Agreement format with the Manufacturer)	41
29.	ANNEXURE-III (Declaration for eligibility in participating the tender)	43
30.	ANNEXURE –IV (Details of EMD submitted)	45
31.	Annexure V –(A certificate from CA OR ICWA for production and financial capacity).	46
32.	Annexure VA in case of importer –(A certificate from CA OR ICWA for financial capacity).	47
33.	ANNEXURE-VI (Annual Turnover Statement)	48
34.	ANNEXURE -VII (List of Items quoted)	49
35.	ANNEXURE -VIII (Check List)	50
36.	ANNEXURE -IX (Details of requirements for Drugs)	52
37.	ANNEXURE –X (Bank Guarantee format for submission of EMD)	79
38.	ANNEXURE -XI ( Details for Manufacturing Capacity & Batch Size)	80
39.	ANNEXURE -XII (Performance Security Bank Guarantee)	107
40.	ANNEXURE -XIII (Agreement format)	108
41.	ANNEXURE -XIV (Declaration for Logogram)	112
42.	ANNEXURE -XV (Packing Specifications)	119
43.	ANNEXURE –XVI (Mandate Form)	122

## **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA**

### **ONLINE TENDER FOR THE SUPPLY OF DRUGS TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA**

#### **FOR THE YEAR 2017-19**

PRADHAN MANTRI BHARTRIYA JANAUSHADHI PARIYOJANA(PMBJP) is the initiative of Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India launching with the noble objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called PRADHAN MANTRI BHARTRIYA JANAUSHADHI KENDRA (PMBJK). BPPI was established in December 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs, and identified as the executing agency for PMBJP.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April, 2010. BPPI follows the provisions of GFR, 2017 as amended from time to time, the CVC guidelines, and instructions from the Department of Pharmaceuticals.

It aims to open more than 3000 stores during current financial year. It is proposed to channelize efforts to popularize PMBJP and ensure availability of the complete basket of medicines at affordable prices.

**Tender Inviting Authority** – C.E.O, Bureau of Pharma Public Sector Undertakings of India, IDPL Corporate Office, IDPL Complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon -122016 (Haryana) (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

**Tender Accepting Authority** – CEO, Bureau of Pharma Public Sector Undertakings of India,(hereinafter referred as **BPPI** unless the context otherwise requires).

**Tender Inviting Authority** invites **Tender for the supply of Drugs to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, for the year 2017-2019.**

## **1. LAST DATE AND TIME FOR SUBMISSION OF ONLINE TENDERS.**

(a) Online Bids [in two separate Cover {Technical bid (“Cover A”) and price bid (Cover “B”)}] will be submitted till **11.00 A.M. up to 13/06/2017(Tuesday)** on CPP portal i.e. eprocure.gov.in.

(b) The price bid shall be valid for a period of 120 days from the date of opening of Technical Bid. Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms & conditions. However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

## **2. ELIGIBILITY CRITERIA**

(a) (i) Tenderer shall be a manufacturer having valid drug manufacturing unit duly licensed by licensing authorities. Loan licensee is also eligible.

(ii) Tenderer shall be direct importer holding valid import license. The Importer should have valid sale license.

(iii) Tenderer shall be a marketer of manufacturer who have exclusive rights to market the products and manufacturer do not market the products duly supported by valid agreement with the manufacturer and in that case BPPI shall sign tri party agreement for supply of drugs if they are eligible for award of contract. **Distributors/Suppliers/Agents are not eligible to participate in the Tenders.** The Marketer should have valid sale license.

(b) (i) Manufacturer should have valid WHO-GMP (World Health Organisation-Good Manufacturing Practices) certificate issued by licensing authority.

(ii) Average Annual turnover of manufacturer in the last three years i.e. 2013-14, 2014-15 and 2015-16 shall not be less than **Rs. 20 Crores**. In case of loan licensees and Marketer, average annual turnover of manufacturer in the last three years i.e. 2013-14, 2014-15 and 2015-16 shall not be less than **Rs. 20 Crores**.

(c) Market Standing Certificate (MSC) issued by the state licensing authority under generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 2 years.

(d) A certificate from their C.A. (Chartered Accountant) or ICWA that they have manufactured & marketed at least 2 commercial batch in last three years.

(e) Non-conviction Certificate not older than 6 month issued by the licensing authority of the State certifying that the firm/company has not been convicted.

(f) A certificate from the C.A. (Chartered Accountant) or ICWA that the bidder has Production & financial capacity to manufacture and deliver the drugs quoted by the firm in the tender as per quantity mentioned in tender during contract period.

(g) Tenderer should not be submitted for the product(s) for which the firm / company has been blacklisted/debarred/de-registered/banned by any State Government / Central

Government / its Drug procurement agencies due to quality failure of the drugs **at the time of submission of online bid.**

(h) The Tenderer should have not been blacklisted/debarred/de-registered/banned due to quality failure for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies **at the time of submission of bid.** Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies during last three years.

(i) During the validity of the tender if the firm / Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI along with relevant authentic document by the tenderer firm/ company within one month.

(j) The tenderer should confirm that they have read tender document including Amendment(s) to Tender document (if any) along with terms and condition and these terms and condition of tender document including Amendment(s) to Tender document (if any) are acceptable unconditionally to them.

(k) Tenderer are required to incorporate bar codes as per GS1 standards at various packaging levels (primary, secondary and tertiary. (**Annexure I**)

### **3. GENERAL CONDITIONS.**

(i) The tender document shall be download from the websites [janaushadhi.gov.in](http://janaushadhi.gov.in); and CPP portal i.e.[eprocure.gov.in](http://eprocure.gov.in). Tender Document is free of cost. No tender cost is to be deposited.

(ii) **EMD (Earnest Money Deposit)** : EMD of Rs.1,00,000/- (Rupees One Lakh only as specified in Clause 7 of the Tender document in the form of **Bank Guarantee or Bankers Cheque or Demand Draft from nationalised/Scheduled Bank** favouring “Bureau of Pharma Public Sector Undertakings of India “, payable at Gurgaon/Delhi **which is to be delivered in original to BPPI, Gurgaon on or before the date stipulated against ‘ Bid opening Date ’.** Name & full address of the bidder may be written at the back of the Demand Draft/Pay Order. Signed and scanned soft copy of the EMD instrument must be uploaded (**ANNEXURE IV**) to the e-Procurement portal. EMD in any other form like *cheque/cash/postal order* etc. **will not be accepted. The Bid (in case not exempted for EMD as mentioned in tender document) without EMD shall be summarily rejected.**

(iii) Tenders will be opened online. However, authorized representatives of bidder who like to attend online bid opening on the specified date and time should bring letter of authority authorising to attend online bid opening on the printed letter head of the company.



(iv) (a) At any time prior to the last date of submission of online bid, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by

an amendment uploading on website on [janaushadhi.gov.in](http://janaushadhi.gov.in); and CPP portal i.e. [eprocure.gov.in](http://eprocure.gov.in) will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of online bid.

(b) Any person who has downloaded the tender document should watch for amendment, if any, on the website [janaushadhi.gov.in](http://janaushadhi.gov.in); and CPP portal i.e. [eprocure.gov.in](http://eprocure.gov.in) for which BPPI will not issue any separate communication to them.

(v) Interested eligible Tenderers may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

(vi) During tender or agreement period, if L1 bidder is debarred/deregistered/blacklisted/banned by any Central Government or state Government or its procurement agencies due to quality failure, BPPI may purchase the drugs from L2 bidder or may go for fresh tender as per discretion of BPPI.

(vii) The BPPI reserves the right to purchase any drugs full or part quantity from PSU as per discretion of BPPI. In case of emergencies, BPPI may go to PSU and price will be as per negotiation and at the discretion of BPPI.

### **3.1 SPECIAL CONDITIONS.**

(i) Bids shall be submitted online only at CPPP website :<https://eprocure.gov.in>. Manual bids shall not be accepted except for the original documents/instruments as mentioned in tender document.

(ii) Bidders are advised to follow the 'Special Instructions to the Contractors/Bidders for the e-submission of the bids online' available through the link 'Help for Contractors' at the e-Procurement Portal <https://eprocure.gov.in>.

(iii) Bidder shall not modify the downloaded tender form including downloaded price Bid template in any manner. In case any tender form/Price bid template is found to be tampered with/modified in any manner, such bid will be summarily rejected, Bid Security would be forfeited and bidder is liable to be banned from doing business with BPPI.

(iv) Bidders are advised to check the website of BPPI: [janaushadhi.gov.in](http://janaushadhi.gov.in) and CPPP website <https://eprocure.gov.in> at least 3 days prior to closing date of submission of tender for any corrigendum, addendum, or amendment to the tender document.

#### **4. TECHNICAL BID - COVER "A"**

**4.1.** The Tenderer should upload the following documents in while submitting technical bid hereafter called "**Cover A**". (Scanned copies of each page of all documents should be uploaded while submitting Technical bid).

(a) (i) ) The marketer of manufacturer who have exclusive rights to market the products and manufacturer do not market the products should upload valid agreement with the manufacturer with technical bid ( **ANNEXURE II**) and **the original agreement should be submitted on or before the schedule date of technical bid opening**. In case, bidder is a marketer of a manufacturer, scanned copy of valid sale license is required to be uploaded. The Importer is also required to upload copy of valid sale license. In case bidder is Importer, it is not mandatory to submit ANNEXURE II but it is advisable to submit the same from their Manufacturer.

(ii) The tenderers are required to upload scanned undertaking on stamp paper duly notarized by authorised signatory confirming they are holding the valid drug license, valid WHO- GMP certificate, 2 years market standing certificate for quoted products issued by licensing authority, a certificate for manufactured & marketed of two batches for quoted drugs within 3 years issued by CA or ICWA , valid Non conviction certificate not older than 6 months issued by licensing authority , valid import license , undertaking as per para 2(h) & (j), undertaking to supply the drug with bar code as per ANNEXURE I and as per Annexure XIV & XIV A , undertaking for Clause 7.2 and also enclosed all undertaking/declaration as per Annexure mentioned in the tender document. In case the bidder is Importer, they may strike the clause or part of clause not applicable in their case.**On the basis of such undertaking, the price bid shall be opened within a week after opening of technical bid. However, the bidder is required to upload/submit all the documents along with the technical bid and in case any document is not complying as per undertaking, their contract/agreement shall be cancelled with forfeiture of EMD/Security Deposit/Bank guarantee. (ANNEXURE – III).**

(b) Earnest Money Deposit as indicated in Clause 3(ii) and Clause 7. of the tender document shall be in the form of **Bank Guarantee or Bankers Cheque or Demand Draft** favouring "Bureau of Pharma Public Sector Undertakings of India " , payable at Gurgaon/Delhi. Tender cost and EMD in any other form like *cheque/cash/postal order* etc. **will not be accepted**. Scanned soft copy of the EMD instrument must be uploaded (ANNEXURE IV) to the e-Procurement portal. and **original EMD instrument should be submitted to BPPI, Gurgaon on or before the schedule date of technical bid opening**.

(c) Documentary evidence for the constitution of the Company/Firm such as Memorandum and Articles of Association, Partnership deed, Permanent Registration Number etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor. The list of

present Directors in the Board of the Company duly certified by a Company Secretary of the Company/Practicing Company Secretary / Chartered Accountant to be uploaded.

(d) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Tenderer as the Authorized signatory of the Company/Firm should be uploaded.

(e) Authorization letter nominating an officer of the Tenderer on the printed letter head of the company to transact the business with the BPPI to be uploaded.

(f) (i) ) A certificate from the C.A.(Chartered Accountant) or ICWA that the bidder has Production & financial capacity to manufacture **(as per format ANNEXURE V)** and deliver the drugs quoted by the firm in the tender as per quantity mentioned in tender during contract period. The certificate should be uploaded along with the technical bid. In case the bidder is Importer, a certificate from the C.A.(Chartered Accountant) or ICWA that the bidder has Financial capacity to manufacture **(as per format ANNEXURE VA)** and deliver the drugs quoted by the firm in the tender as per quantity mentioned in tender during contract period. The certificate should be uploaded along with the technical bid. **The original Certificate (ANNEXURE V /ANNEXURE VA) should be submitted on or before the schedule date of technical bid opening.**

(ii) Average Annual Turnover certificate from Chartered Accountant of manufacturer ( including loan licensees and Marketer ) in the last three years i.e.2013-14, 2014-15 and 2015-16 certifying not be less than **Rs. 20 Crores is required to upload as per format(ANNEXURE-VI).The certificate from C.A. (Chartered Accountant) is required to upload as per format(ANNEXURE-VI).**

(g ) The Tenderer should upload Scanned copy of valid drug Manufacturing Licence for the product, duly approved by the Licensing Authority for each and every product quoted as per specification in the tender. The licence must have been duly renewed up to date and the items quoted shall be clearly highlighted in the licence. Original documents should be produced for verification when demanded. However, if renewal application for manufacturing licence has been filed, Scanned copy of same duly receipted by drug authorities must be uploaded along with the validity certificate from state licencing authority (SLA).

(h) Scanned copy of import license (in Form 10 with Form 41), as per Rule 122A of the Drugs and Cosmetics Act 1940, if the product is imported should be uploaded. The licence must have been renewed up to date. A copy of a valid licence for the sale of Drugs imported by the firms issued by the State Licensing Authority shall be uploaded. Original documents should be produced for verification when demanded.

(i) MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY UNDER generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 2 years (Certificate should be uploaded with list of items).In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be uploaded. MSC issued under brand name or under generic name (by the state licensing authority) will also be accepted but **supplies will be accepted as per packing and label by foreign manufacturer in their brand subject to affixing sticker for Logo as approved by**

**BPPI & BPPI MRP.** However, for those newly launched drugs whose first product permission to manufacture and sale has been issued within 2 years by the respective country's / state drug authority, MARKET STANDING CERTIFICATE (MSC) issued by the respective country's /STATE LICENSING AUTHORITY under generic or brand name as a Manufacturer for less than 2 years shall be acceptable to BPPI. In case the bidder is Importer, MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY shall not be applicable.

(j)The bidder should upload a certificate from their C.A.(Chartered Accountant) or ICWA that they have manufactured & marketed at least 2 commercial batch in last three years. The details of commercial batch no., month of manufacture, batch size in last three years period duly certified by their C.A. or ICWA should be uploaded along with technical bid. In case the bidder is Importer also, a certificate from their C.A.(Chartered Accountant) or ICWA that they have manufactured & marketed at least 2 commercial batch in last three years. The details of commercial batch no., month of manufacture, batch size in last three years period duly certified by their C.A. or ICWA should be uploaded along with technical bid.

(k) The copies of relevant pages indicating quoted product passed successfully in Bio-equivalence studies from DCG(I) approved centres/ laboratories/drug authorities of concerned country for imported drug, if any should be uploaded along with technical bid.

(l) Scanned copy Non-conviction Certificate issued by the licensing authority of the State certifying that the firm/company has not been convicted should be uploaded. **The certificate should not be more than 6 months old at the time of submission of technical bid.**

(m) Scanned copy of Valid WHO-GMP(World Health Organisation-Good Manufacturing Practices) Certificate (for manufacturer only) issued by the Licensing Authority should be uploaded. In case of Imported drugs , labels and product literature of all quoted product(s) must be uploaded COPP certificate as per WHO format of their Principal Manufacturing company/firm.

(n) a. Scanned copy of Latest Sales Tax Clearance certificate/returns are to be uploaded (In case Sales Tax is exempted, the documentary evidence with nil returns are to be uploaded).

b. Scanned copy Latest Income tax assessment orders/returns filed are to be uploaded.

In case, bidder is a marketer of a manufacturer, the latest Sales Tax Clearance certificate/returns and the latest Income tax assessment orders/returns of bidder as well as of their manufacturer/manufacturers are to be uploaded.

(o) Documents, if any, to show that the manufacturing unit/importer has been recognized by any other Indian / International Standard Organizations etc. as applicable.

(p)The loan license bidder are required to upload scanned copies of all the documents as per tender requirements including manufacturing unit.

(q) List of items quoted (The name & Drug code of the Items quoted as shown in the **ANNEXURE-VII** should be uploaded and **the rate of those items should not be indicated in this list**).

(r) A Checklist (**ANNEXURE- VIII**) shall be uploaded with technical bid. If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will be uploaded as a separate set with the same tender. However, one bidder will be allowed to submit only one offer for one product.

(s) All the documents uploaded should also be signed by the authorized official of the Tenderer.

**4.2.** The all documents indicated above should be uploaded and shall be opened at the time of Technical bid opening.

## **5. PRICE BID - COVER "B"**

**5.1.** Cover "B" contains the Price Bid of the Tenderer.

(i) The Tenderer shall fill in offering Bioequivalence product(Yes/No), Shelf life ,the landed price, total value, rate of CST against form C and Central excise duty applicable(yes/no) in respective column of for the items quoted and also in BOQ. **In case, any product is offering Bioequivalence, only copies of relevant pages indicating quoted product passed successfully in Bio- equivalence studies from DCG(I) approved centres/ laboratories/drug authorities of concerned country for imported drug should be uploaded on line with technical bid**

(ii) **Determination of L1 bidder:**

(a) In determining the lowest evaluated price, the rate quoted per unit landed price as indicated in column No. 7 of the **BOQ** shall be taken into consideration.

(b) The Price preference up to 10% over L1 bidder (if not offering bio-equivalent product) shall be given to the bidder having Bio-equivalence studies from DCG(I) approved centres/laboratories /drug authorities of concerned country for imported drug and the bidder offering Bio-equivalence studies shall be awarded contract.

(c) The bidders are required to offer maximum shelf life of their quoted product complying Drug & Cosmetic Act 1940 and rules 1945 amended up to date if any. Additional price preference up to 2% per extra quarter (three months) of shelf life subject to maximum 10% ( 5 quarters i.e. 15 months) over L1 bidder shall be given to the bidder who offers shelf life more than L1 bidder and the bidder offering higher shelf life shall be awarded contract.

**Note 1:- (a) No price preference for comparatively higher shelf life shall be given if L1 bidder is offering bioequivalent product. However, price preference for higher bidders offering bioequivalent product shall be given as mentioned above.**

**(b) If L1 bidder is not offering bioequivalent product, the price preference shall be applicable as mentioned above and preference shall be given to bioequivalent product irrespective of lower shelf life.**

**Note 2:- Ceiling of total 20% Price preference on account of Bioequivalence product and higher shelf life shall be applicable.**

**Note 3:- Later on, if product does not comply Bioequivalence or shelf life as declared in tender, the extra price paid to the supplier shall be recovered in addition to other penal action.**

(iii) The rate quoted in column 7 of **BOQ** should be for a unit and for the given specification. **The rates quoted should be in rupees and paisa up to 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the ANNEXURE-IX

#### **EXCISE DUTY-**

(vi) The tenderers must indicate the rate of Excise duty applicable and payable by them irrespective of the fact whether the quoted prices are inclusive or exclusive of Excise Duty. If a tenderer states that the Excise duty is NIL/EXEMPTED, he must intimate the basis for the same and also confirm that no Excise Duty will be charged by him under any circumstances.

(vii) In case, no information about excise duty is given, it will be taken as inclusive.

#### **ST/CST/VAT**

(viii) The tenderers must indicate the rate of CST **against Form C** applicable.

(ix) In case supply is made from any place in Haryana, VAT shall be applicable.

**(x) During agreement period if GST is implemented, ED,CST with form C / VAT shall be substituted by GST as per notification Government of INDIA.**

**(xi)** The bidder is required to indicate CST in % only against form C as indicated in the heading of column BOQ and not to indicate amount of CST in Rs. at particular cell of excel sheet of BOQ. For ED, there is a separate column where bidders are required to indicate ED applicable i.e. **yes or No.**

#### **6. OPENING OF COVER “A” AND COVER “B” OF TENDER**

**6.1** Only authorized official as indicated in Clause 4.1. (e) are entitled to be present at the time of opening of Technical Bid - Cover “A” of the tender submitted by them.

**6.2** Tenderers, who are found eligible on satisfying the criteria for technical evaluation/based on undertakings & Declaration, will only be informed the time and date of opening of Price Bid - Cover “B” of the tender.

6.3 In case, the date for opening of technical bid is declared holiday, the technical bid shall be opened on next working day at 11.30 A.M.

## **7. EARNEST MONEY DEPOSIT**

**7.1.** The Earnest Money Deposit referred to under Clause 3(ii) & 4.1(a), shall be **Rs. 1 lakh. The Earnest Money Deposit shall be paid in the form of Bank Gurantee or Bankers Cheque or Demand Draft in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, payable at Gurgaon/Delhi. In case EMD in form of Bank Guarantee, Irrevocable Bank Guarantee** in favour of Bureau of Pharma Public Sector Undertakings of India from any Nationalised/scheduled Bank should be valid for a period beyond **270 days/9 months from the date of tender opening.** The format of Bank Guarantee is at **ANNEXURE-X.** BPPI will not pay interest on any deposit held in the form of **Bankers Cheque or Demand Draft.**

**7.2. (i)** The tender submitted without sufficient EMD will be summarily rejected.

(ii) The Earnest Money Deposit will be refunded to the successful bidders within 30 days from the date of signing the contract agreement and on the deposit of Security Deposit.

(iii) The Earnest Money Deposit (EMD) of the unsuccessful bidders will be returned after finalization of tender/signing of agreement with eligible bidder.

(iv) The Earnest Money Deposit (EMD) will be forfeited, if the tenderer withdraws his bid any time after opening of price bid / non execution of agreement /undertaking within the period prescribed.

(v) The Earnest Money Deposit (EMD) will be forfeited, in case of the lowest bidder, fails to execute the contract agreement and / or deposit the security Deposit within the stipulated time. The EMD shall be forfeited if the undertaking as Annexure II is not found correct.

(vi) Tenderer may be exempted from the payment of EMD, if valid **registration** certificate from NSIC is uploaded **for the product for which bidder has submitted quotation.**

(vii) PSUs are exempted from the payment of EMD.



## **8. OTHER CONDITIONS**

**8.1.(i)** The details of the required drugs, medicines, etc., are shown in **ANNEXURE - IX. *The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased*** by the BPPI, at its discretion, depending on its actual need. Though the tentative quantity is indicated in the agreement, the BPPI, will confirm the actual requirement then / there through purchase order/orders. The tenderers shall supply the drugs only on the basis of the purchase order issued time to time within validity of contract period by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.

(ii) The Tenderer shall fill in manufacturing capacity per year in units, Shelf life in months and manufacturing batch size in units for each quoted drugs in required column of **ANNEXURE –XI and upload along with technical bid**. In case the bidder is Importer, the importer is required to sign and upload ANNEXURE XI on behalf of the exporter which would be supported by documentary evidence provided by the manufacture

(iii) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the agreement / undertaking.

(iv) The rates quoted shall not be varied with the ordered quantity during the full contract period.

**8.2.** Tender has been called for in the **Generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in **ANNEXURE-VIII**. Any variation, if found, will result in rejection of the tender. However the imported/combination drugs are allowed to quote in trade / brand name.

**8.3.** Rates (inclusive of Customs duty, packing & forwarding charges, transportation, insurance and any incidental charges, but exclusive **CST against form C/VAT** (Sales Tax) and excise duty) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like “AT CURRENT MARKET RATES” shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

**8.4.** Each bid must contain not only the unit rate but also the total value of each item quoted for supply in the respective columns. The aggregate value of all the items quoted in the tender shall also be furnished.



**8.5. (i)** The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer. Tender Inviting Authority at its discretion, may exercise, the right to revise the price at any stage so as to conform to the controlled price or MRP or the selling price of the tenderer as the case may be. This discretion will be exercised without prejudice to any other action that may be taken against the Tenderer. In case delivery of drugs is not made within delivery period mentioned in Purchase order, the supplier must confirm from BPPI whether BPPI MRP is to be reduced due to changes in DPCO ceiling rate after issue of purchase order.

**(ii) FALL CLAUSE:**

If at any time during the execution of the contract, the controlled price becomes lower or the supplier reduces the sale price or sells or offers to sell such stores, as are covered under the contract, to any person / organization including the purchaser or any department of Central government/state Govt. or its procurement agencies at a price lower than the price chargeable under the contract, he shall forthwith notify such reduction or sale or offer of sale to the purchaser and the price payable under the contract for the stores supplied after the date of coming into force of such reduction or sale or offer of sale shall stand correspondingly reduced.

**8.6.** The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly, this clause will be applicable for all orders placed during the contract period. **However, agreement validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.**

**8.7.** No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

**8.8.** Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

**8.9.** The Tenderer shall allow inspection of the factory at any time after the opening of technical bid and during the entire contract period by a team of Experts/Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/Firm does not allow for any such inspection, their tenders will be rejected. If

any such situation arises after placement of contract, the same shall be cancelled at the firm's risk cost.

**8.10** "MRP inclusive of all taxes" is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

## **9. ACCEPTANCE OF TENDER**

**9.1. (i)** Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done on the basis of rate per unit landed price as mentioned in column 7 of **BOQ considering price preference for bioequivalent product and higher shelf life** . **However**, to have additional source of supply, the L1 bidder shall be awarded contract/agreement for 50% of tender quantity indicated in the tender document. Balance 50% of the tender quantity indicated in the tender document shall be awarded to **L2 & L3 bidders or higher bidders quoted rates in ascending order having same or higher Shelf life that of L1 bidder in the ratio of 30:20 respectively if they agree to supply the drugs at L1 rates. In case only 2 bids, the L1 bidder shall be awarded contract/agreement for 50% of tender quantity indicated in the tender document quantity. Balance 50% of tender quantity shall be awarded L2 bidders having same or higher Shelf life at L1 rate.**

(ii) In case, either of L2 or L3 bidder does not agree to match L1 rate, balance 50% quantity shall be awarded to any of these two bidders who agrees to match L1 rate. In case, both L2 and L3 bidders do not agree to match L1 rate, 100% tender quantity shall be awarded to L1 bidder. The purchase order shall be issued to L1 bidders and in case they fail to supply in stipulated time, the purchase order shall be issued to L2 bidder. Similarly, if L2 bidder fails to supply drug in stipulated time, the purchase order shall be issued to L3 bidder. During the agreement period of 2 years, in case L1 bidder completes the supply of drugs for contracted quantity, next supply shall be taken from L2 & L3 bidders accordingly for contracted quantity. However, if any supplier fails to supply the drugs due to quality failure or any other reason during agreement period of two years, such quantity shall be distributed to remaining suppliers.

(iii). The issue of purchase orders in same manner as mentioned above. Negotiation if required will be done at our premises and the same will be done strictly as per Central Vigilance Commission guidelines.

**Note 1.:- No quantity distribution shall be applicable if (i) Only one bid is available (ii) Same L1 rates quoted by more than one bidder keeping in view of sharing of quantity as per clause no. 11(c) (iii)L1 bidder is offering bioequivalent product and (iii) higher bidder/bidders have offered lower Shelf life.**

**2. (a) If tender quantity of any drug is upto 50000 unit size, full tender quantity of that drug shall be placed on L1 bidder.(b) If tender quantity of any drug is more than 50000 unit size and up to 1,00,000 unit size,, full tender quantity of that drug shall be distributed in ratio of 50:50 to L1 and L2 bidder.(c ) If tender quantity of**

**any drug is more than 1,00,000 unit size,, full tender quantity of that drug shall be distributed in ratio of 50:30:20 to L1 , L2 and L3 bidder.**

**9.2.** BPPI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

**9.3.** BPPI or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections.

**9.4.** The acceptance of the tenders will be communicated to the Tenderers in writing.

## **10. SECURITY DEPOSIT AND AGREEMENT**

### **10.1 Security Deposit:**

On being informed about the acceptance of the tender and at the time of signing the Agreement, the Tenderer shall pay the Security Deposit @5% of **value of 50% quantity i.e. one year quantity out of 2 years quantity of agreement signed** in the form of ***Demand Draft or irrevocable Bank Guarantee*** in favour of Bureau of Pharma Public Sector Undertakings of India from any scheduled Bank. In case the Security Deposit is paid in form of Bank Guarantee, the bank guarantee shall be valid for a period beyond **one year of the validity of the agreement**. The format of Bank Guarantee is at **ANNEXURE-XII**.

**10.2.** The Tenderer shall execute an agreement on a non- judicial stamp paper of value of Rs.100/- (stamp duty to be paid by the Tenderer) within 15 days from the date of the intimation from BPPI informing that his tender has been accepted. The Specimen form of agreement is available in **ANNEXURE-XIII**.

**10.3.** The Tenderer shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons what so ever.

**10.4.** All notices or communications relating to and arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if delivered to him or left at the premises, places of business or abode as provided by the tenderer.

**10.5.** If the lowest selected Tenderer fails to execute the agreement and/or to deposit the required security deposit within the time specified or withdraws the tender, after the intimation of the acceptance of the tender or owing to any other reasons to undertake the contract, the contract will be cancelled and the Earnest Money Deposit deposited by the tenderer along with the tender shall stand forfeited by the BPPI and the firm will also be liable for all damages sustained by the BPPI apart from blacklisting and other penal

actions. The security deposit shall be forfeited if the undertaking as Annexure II is not found correct.

**10.6.** The security deposit of supplier will be returned by BPPI only after the supplier has given undertaking to replace such medicines and indemnify BPPI against any losses on account of quality parameters.

## **11. METHODOLOGY FOR PLACING ORDERS**

For the above purpose the following procedures will be adopted

(a) After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed.

(b) The Successful Tenderer is eligible for the placement of Purchase Orders only after depositing the required amount as Performance Security and on execution of the agreement.

(c) If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers shall execute necessary agreement as specified in the Tender Document on depositing the required amount as Performance Security and on execution of the agreement such Tenderers are eligible for the placement of Purchase Orders for such item(s) for which they are declared as lowest. Placement of order shall be shared equally amongst these bidders subject to their manufacturing capacity.

(d) In the case of purchase of goods where the quantity offered at the lowest price is less than the total quantity required, the BPPI may, after placing orders with the lowest evaluated Tenderer for the entire quantity offered by such Tenderer subject to his ability to supply, require all the other eligible Tenderers who participated in the tender and offered a price higher than that offered by the lowest evaluated Tenderer, to submit sealed offers of the quantity they would be willing to supply at the price quoted by the lowest evaluated Tenderer, and thereafter place orders for the remaining required quantity with all those who match the lowest evaluated price such that those who bid lower prices in the original tender get a higher priority for supply.

(e) If a supplier fails to execute supply order, the 5% value of supply order shall be recovered from pending bill or EMD/Bank Guarantee and their bad performance shall be kept in record of BPPI for future dealing as considered appropriate by BPPI.

(f) Notwithstanding anything contained in para (e) above, the supplier, after committing the default in supply either partly or fully, can inform the BPPI about his willingness to execute the Purchase Order during the tender period. The BPPI at discretion may consider

the willingness of the supplier on merit. However, such supplies will be subjected to the levy of Liquidated Damages, unexecuted fine and other penalties as stipulated in the tender document, agreement and purchase order.

(g) The supplier shall start supply of the Drugs/Medicines required by BPPI at Central Ware House (CWH), Gurgaon or any other place decided by BPPI within the stipulated period.

(h) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

(i) The supplier shall supply the Drugs/Medicines at the CWH, Gurgaon along with copy of Purchase order, copy of test reports and 3 original copies of Invoice. No payment will be processed without test reports.

(j) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also the supplier shall ensure the quantity relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice.

(k) It is the duty of the supplier to supply Drugs/Medicines at the CWH Gurgaon or any other place decided by BPPI and supply shall conform to the conditions mentioned in the provisions of tender documents, viz., logo, nomenclature, specification etc.,

(l) Subject to above, BPPI will process the invoices submitted by the supplier and the payments against supply will be made within 30 days from the date the Drugs/Medicines supplied has been declared of STANDARD QUALITY, by the Empanelled laboratory of BPPI subject to various terms and conditions of the tender.

(m) Subject to the conditions mentioned in the Purchase Order, Tender Document, Agreement executed by the supplier and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 30 days from the date of receipt of payment, failing which BPPI will not entertain any claim thereafter.

(n) BPPI reserves the right to place upto 50% additional purchase order of the quantities as contracted within validity of contract.

## **12. SUPPLY CONDITIONS**

**12.1.** Purchase orders will be issued to the Tenderer(s) at the discretion of the BPPI as per actual requirements. All the supplies shall be received at the central warehouse at Gurgaon or any other place decided by BPPI.

**12.2.** Within 3 days from the receipt of purchase orders the Tenderer should inform BPPI through fax and mail the confirmation for the receipt of the purchase order.

**12.3.** The Tenderer should also fax and mail the details of supply dates as specified in Annexure, to BPPI within 7 days from the receipt of the purchase order. In case, the supply shall not be made by the date as conveyed by the supplier, supply order shall be cancelled at their risk and cost. If no response is received within 7 days from the supplier / tenderer about supply of drugs as per purchase order, it shall be presumed that the supplier/tenderer is not interested to supply the drugs ordered as per purchase order and BPPI shall purchase the drugs from alternative sources.

**12.4. (a)** For the first purchase order, the supplier must supply the ordered quantity CWH Gurgaon within 50 days from the date of Purchase Order.

(b) For Subsequent purchase orders, the supplier shall complete the supply within 40 days from the date of purchase order at the destinations mentioned in the purchase order.

(c) If the above day for 12.4 (a) &(b) above happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day.

(d) In case of Non- execution of the order, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information.

(e) If the Tenderer fails to execute the supply within the stipulated time, the BPPI is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 18.

(f) The liquidated damages as specified in clause 18.1 and 18.2 of the tender conditions will be levied on the quantity supplied after the 50<sup>th</sup> day and 40th day for 12.4 (a) &(b)

respectively. However, no supplies will be accepted after 80<sup>th</sup> days/ 70 days for 12.4 (a) &(b) respectively from the date of issue of purchase order and the purchase order shall be cancelled at the risk and cost of the supplier. **However, the supplier must take prior approval from BPPI for supply of drugs beyond stipulated delivery period in Purchase order.**

**(g) In case, the supplier supplies the drugs earlier than stipulated delivery period in supply order, the supplier shall be given incentive @ 2% per week over the rate mentioned in purchase order. No incentive shall be given for earlier delivery of drugs less than a week or part of week.**

**12.5.** Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders. **Further, supplies ordered against a purchase order are to made in minimum numbers of batches as far as possible and same batch should not be supplied in repeated consignment.**

**12.6.** The supplied Drugs (covered in SCHEDULE “P” of Drugs and Cosmetics Act) should have the prescribed potency throughout the shelf life period as prescribed in the Drugs and Cosmetics Act 1940 and rules there under and in relevant Pharmacopoeias. **However, in case of thermolabile drugs not covered in SCHEDULE “P” of Drugs and Cosmetics Act, the minimum shelf life should be 2 years from the date of manufacture.**

**12.7.** The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned back to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs supplied by the successful Tenderer shall be of the best quality and shall comply with the specifications, stipulations and conditions specified in the tender.

**12.8.** Tenderer should supply the product **(a) within 2 months from the date of manufacture of products having shelf life upto 2 years, (b) within 3 months from the date of manufacture of products having shelf life more than 2 years & upto 3 years and (c) within 4 months from the date of manufacture of products having shelf life more than 3 years.** Products beyond the above mentioned period from the date of manufacture shall not be accepted. For example, product having manufacturing of November 2017 must be supplied before Jan 31, 2018 in case shelf life less than 2 months.

For imported products, 60% of shelf life should be available at time of supply.

**12.9.** If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However, such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The exceptional events does not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.



**12.10.** The supplier shall not be liable to pay LD and forfeiture of security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

### **13. LOGOGRAMS**

Logogram means, wherever the context occurs, the design as specified in **ANNEXURE-XIV. The name of the drug shall be mentioned in English and Hindi.**

**13.1.** Tenders for the supply for Drugs etc., shall be considered only if the Tenderer gives an undertaking that the product(s) will be prepared as per the specifications such as name, strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc as per the design enclosed as per **ANNEXURE –XIV &XIV-A.**

**13.2.** All tablets and capsules have to be supplied in packing as specified in product list (**ANNEXURE IX**) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned back at supplier's cost.

**13.3.** Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed Jan Aushadhi logogram of proportionate size.

**13.4.** Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of agreement / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However, if such failure continuous despite notice, will be viewed as a serious lapse and initiate blacklisting of the supplier.

Tenderers who are not willing to agree to conditions above will be summarily rejected.

**13.5.** For imported Drugs, the supplies will be accepted as per packing and label by foreign manufacturer in their brand subject to affixing sticker for Logo as approved by BPPI & BPPI MRP.

### **14. PACKING**

**14.1.** The drugs shall be supplied in the package specified in **ANNEXURE -IX** and **ANNEXURE -XV** and the package shall carry the logograms of proportionate size specified in **ANNEXURE –XIV, XIV -A.** Non affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 18.5

**14.2.** The minimum size of each tablet should be 6.4 mm in diameter and the minimum size of the blister packing and strip packing should be 70mm x 30 mm and 50mm x 130 mm respectively. The drugs in any dosage form to be supplied by the supplier should not



embossed indicating any code no./logo or name company. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5.

**14.3.** The packing in each carton shall be strictly as per the specification mentioned in **Annexure-XV**. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM(**off white/grey is not acceptable**). **The material to be used for carton should be from virgin chemical pulp.** Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label.

**14.4.** The cap of bottle preparations should not carry the name of the supplier.

**14.5.** The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intra Muscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

**14.6.** It should be ensured that only first-hand virgin packaging material of uniform size, including bottle and vial, is used for packing.

**14.7.** All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

**14.8.** Packing should be able to prevent damage or deterioration during transit.

**14.9.** In the event of items of drug supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 18 & 19.

**14.10.** Designs of packaging with the logograms shall be subject to approval by BPPI within 3 days of receipt of the same from the supplier, as per the specifications with soft copy of STP(standard testing procedure) for Non- Pharmacopoeil drugs as per clause 15.1.1. In case of failure of BPPI to do so, the supplier may go ahead with the design as per the specification in **ANNEXURE XIV and XV**.

## **15. QUALITY TESTING**

**15.1.** Samples of supplies from each batch will be chosen at the point of despatch at supplier's site or receipt of supply or distribution/storage points for testing at discretion of BPPI. The samples will be sent to different laboratories including Government Drugs Testing Laboratory for testing as decided by the BPPI Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 17.

**15.1.1** For Non- Pharmacopoeil drugs, supplier should send soft copy of STP(standard testing procedure) by mail to Quality and Regulatory officer of BPPI with art work approval for design of packaging with the logogram as per Clause 14.10.

**15.2.** The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found “Not of Standard Quality”, the cost of entire batch paid will be recovered whether consumed fully/partially. Also action will be initiated for blacklisting as per clause No.19 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

**15.3.** In the event of the samples of Drugs supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 19.

**15.4.** The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the BPPI. In case of any complaint in the field, the B.M.R/B.P.R for the particular batch of the product(s) supplied shall be produced when demanded.

**15.5.** The products should conform to the standards of IP/BP/USP/EP/JP as the case may be. In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs, respective Country’s Pharmacopoeial standards shall be acceptable (even if the product is official in IP).

**15.6.** The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 19. If such lapses happens more than twice in a tender period such cases will be treated as “Misbranded Drugs”.

## **16. PAYMENT PROVISIONS**

**16.1.** No advance payments towards costs of drugs, medicines etc., will be made to the Tenderer.

**16.2.** Payments towards the supply of drugs will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original (**ANNEXURE -XVI**) to make the payment through RTGS/Core Banking/NEFT.

**16.3.** All bills/Invoices should be raised in triplicate and in the case of excisable Drugs , the bills should be drawn as per Central Excise Rules in the name of Bureau of Pharma Public Sector Undertakings of India. IDPL Complex, Dundahera, Gurgaon 122016 or in the name of any other authority as may be designated.

**16.4. (i)** Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI.

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

(a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within delivery period stipulated in purchase order from the issue of such purchase order.

(b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid within 60 days from the date of last supply.

(c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.

**16.5.** If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

**16.6.(a)** In case of any increase of decrease in the taxes, such as excise duty, customs duty, sales tax, VAT etc., after the date of submission of tenders and during the tender period, such variation in the taxes will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned Excise authorities and also must claim the same in the invoice separately. However the basic price structure and the price of the Drugs approved under the tender shall not be altered.

Similarly, if there is any reduction in the taxes and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender.

Any increase or decrease in taxes and statutory levies will be considered based on the notification issued by the Government.

However, if the firm supplies after originally stipulated Delivery period, increase in Excise duty/taxes due to statutory variation in Excise duty/taxes shall be borne by the supplier. In case of decrease in Excise duty/taxes due to statutory variation in Excise duty/taxes, the same shall be passed on by the supplier to the BPPI.

(d) In case of successful bidder enjoying excise duty exemption on any criteria of turnover, area based etc., such bidder will not be allowed to claim excise duty at a later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.

**16.7.** Form 'C' shall be provided by BPPI, wherever required. The tenderers should quote the concessional rate of CST applicable in their bids.

#### **17. HANDLING & TESTING CHARGES:**

No handling & testing charges shall be applicable..

#### **18. LIQUIDATED DAMAGES AND OTHER PENALTIES:**

**18.1.** If the supply reaches the designated places or Central Warehouse after 5 PM of **50th day** from the date of issue of the 1st purchase order and after 5 PM of the **40th day** from the date of issue of the subsequent purchase order, a liquidated damages will be levied at 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply. If the 50<sup>th</sup>/40<sup>th</sup> day happens to be a holiday the supply will be accepted on the next working day without any penalty.

**18.2.** If the supply is received in damaged condition, open delivery of the supplies shall be received, wherein it is possible to physically inspect the shipment. Damaged products shall not be accepted.

**18.3.** All the Tenderers are required to supply the product(s) with printed logogram of appropriate size on the strips, blisters, vials, ampoules& bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product and/or a separate damages will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.14.11 and 13.4.

#### **19. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:**

**19.1.** If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the issue of the letter from the BPPI. Such stock shall be taken back at the expense of the Tenderer. Further, actual handling and testing charges shall be paid to BPPI by the supplier otherwise these charges shall be

recovered from their pending bill/EMD/security deposit. The BPPI has the right to destroy such “NOT OF STANDARD QUALITY DRUGS” if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the “NOT OF STANDARD QUALITY DRUGS” after the expiry of 30 days mentioned above without further notice, and shall also collect demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated. Further, the cost of disposal shall be recovered from the supplier.

**19.2.** If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description (Adulterated/Spurious/Misbranded) or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of “NOT OF STANDARD QUALITY” whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

**19.3.** For the supply of Adulterated/Spurious/Misbranded, as defined in the Drugs and Cosmetics Act, 1940, to BPPI, BPPI reserves the right to blacklist the supplier. No further supplies shall be accepted from the firm/company. If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs for a period of 5 years from the date of blacklisting. In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs for a period of 2 years from the date of blacklisting. In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Security deposit will also be forfeited without any intimation.

**19.4.** The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders, if the source of supply is not furnished.

**19.5.** The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the BPPI will be at liberty to terminate, the contract either wholly or in part on 30 days' notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Security deposit.

**19.6.** For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Security deposit.

**19.7.** Non-performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years besides forfeiture of Security deposit.

**19.8.** In the event of making Alternative Purchase, as specified in Clause 12.4 (a), Clause 14.11 and in Clause 15.3 penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

**19.9.** In all the above conditions, the decision of the BPPI shall be final and binding.

## **20. BLACK LISTING IN THE EVENT OF WITHDRAWAL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE**

### **20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER**

(a) If the Tenderer(s) fails to execute the agreement / to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be blacklisted for a period of 2 years by BPPI from the date of observing the defect besides forfeiture of Security deposit.

### **BLACKLISTING FOR QUALITY FAILURE**

#### **20.2.1. Quality Test by the Empanelled Laboratories of BPPI**

a. Each and every batch of drugs/medicines shall be subjected to quality test by the Empanelled laboratories.

b. The samples collected from each batch of supply of the each drugs will be sent to the empanelled testing laboratories for testing the quality of drugs. In addition to the above BPPI shall also draw the samples of products supplied in the market place and get the same tested, to make sure the products are conforming to quality requirements.

c. If such sample passes quality test in all respects, BPPI will instruct its Warehouse to release such items of drugs.

d. If the sample fails in quality test and report is received certifying that sample is “NOT OF STANDARD QUALITY” then supplies will be rejected & no further procurement of that drug from the supplier for two years from the date of sample being declared not of standard quality. If the supplier challenges and request for re- testing, the rejected supply



shall be tested in two labs simultaneously at the cost of supplier. The cost testing shall be recovered from the supplier.

(i) If such sample passes the quality test in both laboratories, the drugs representing the sample shall be qualified for issue to various Institutions.

(ii) If the sample passes in one laboratory and fails in other laboratory or fails in both laboratories, the supply shall be rejected. No further procurement of said drug shall be made from such supplier.

(iii) If 3 batches of item/drug supplied by the same supplier is reported to NOT OF STANDARD QUALITY in specification, then the firm shall be blacklisted for 2 years after observing procedure laid down in Para 20.2.3 besides forfeiture of Security Deposit.

#### **20.2.2 Quality Test by Statutory Authorities:**

(a) If any drug is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals/JAS will be retrieved.

(b) If any batch of any product(s) supplied by the company/firm declared, NOT OF STANDARD QUALITY in specification as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during the relevant tender period or during quality check within shelf life period, the company/firm shall be blacklisted for a period of 2 years from the date of blacklisting after observing procedure laid down in Para 20.2.3.

#### **20.2.3 Procedure for Blacklisting:**

(i) On receipt of complaint from Distributer/retailers/customers or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is “**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/MISBRANDED**” (As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the item of the product/company or firm as deemed fit besides forfeiture of Security deposit

(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular item floated by the BPPI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

### **20.3 BLACKLISTING FOR NON-SUPPLY:**

Due to non supply of item against any purchase order, 5 % value of purchase order shall be recovered from the supplier in addition of other penal like risk purchase. In case of repeated circumstances of non supply of items i.e. 3 times , the supplier may be blacklisted for 2 years in addition of forfeiture of security deposit/ EMD and other penal action.

### **21. SAVING CLAUSE**

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

### **22. RESOLUTION OF DISPUTES**

(i) The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract,

### **ARBITRATION AND JURISDICTION**

Normally, there should not be any scope of dispute between the BPPI and the supplier after entering into a mutually agreed valid contract/agreement.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/agreement leading to disagreement BPPI and the supplier shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the supplier shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be final and binding on the parties.

### **23. APPEAL:**

(i) Any Tenderer aggrieved by the order passed by the Tender Accepting Authority under section 10 of the said Act, may appeal to the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India within ten days from the date of receipt of order and the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India shall dispose the appeal within fifteen days from the date of receipt of such appeal.

(ii) No Appeal shall be preferred while the tender is in process and until tender is finalized and Notification of award is issued by the BPPI.

### **24. CONTACTING THE BPPI BY THE BIDDER:**

(i) No bidder shall contact the *BPPI* on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.



(ii) Any effort by a bidder to influence the *BPPI* in the *Purchaser's* bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.

(ii) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

(iv) Notwithstanding anything contained in clause (iii) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

## **25. FRAUDULENT AND CORRUPT PRACTICES:**

### **(1)For bidders:**

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. *(In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper)* In pursuance of this policy, the purchaser;

(a) defines, for the purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party (*"another party" refers to a public official acting in relation to the procurement process or contract execution*). *In this context, "public official" includes staff and employees of other organizations taking or reviewing procurement decisions.*

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (*a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution*).

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party [*"parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non competitive level*].

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (*a "party" refers to a participant in the procurement process or contract execution*).

(v) “obstructive practice” is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser’s inspection and audit rights provided for under sub-clause (e) below.

(b) will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

(c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub contractors engaged in corrupt, fraudulent, collusive, or coercive practices.

(d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

(e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

## **(2) For suppliers:**

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Security Deposit apart from other penal actions.

(a) For the purposes of this Sub-Clause:

(i) “corrupt practice” is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;

(ii) “fraudulent practice” is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

(iii) “collusive practice” is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;

(iv) “coercive practice” is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;

(v) “obstructive practice” is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the

investigation; or (bb)acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for.

**26. JURISDICTION**

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

-----

## ANNEXURE I

### (BARCODE REQUIREMENTS}

Reference clause 2(k)

#### **GS1 barcode requirements on Drugs procured by Bureau of Pharma Public Sector undertakings of India (BPPI)**

These requirements cover medicines/drugs procured by Bureau of Pharma Public Sector Undertakings of India (BPPI), Gurgaon, meant for supply and distribution through BPPI regulated distribution channel.

Barcode based on GS1 identification standards are provided below at various levels of product packaging which includes primary, secondary and shipper/carton levels and need to be complied with while supplying medicines/drugs to BPPI.

GS1 India is unique identification & barcoding standards body setup by Ministry of Commerce & Industry, Govt. of India along with APEDA, BIS, Spices board, IIP and apex industry chambers like CII, FICCI, ASSOCHAM to assist India industry and govt. bodies on adoption of global standards.

Suppliers are also required to provide GS1 subscription validity certificate at the time of supply of medicines/drugs issued by GS1 India. For validity certificate suppliers can contact GS1 India at 011-4289-0890

Barcodes based on GS1 global standards are required to be printed on product packaging at primary, secondary and tertiary packaging levels **in addition** to other, existing statutory labelling & marking requirements.

#### **Technical Specification for GS1 Standards**



##### **Tertiary Level Pack:** Data attributes captured

- a) *Unique product identification code (GTIN - Global Trade Identification Number)*
- b) *Expiry date*
- c) *Batch no.*
- d) *Quantity*
- e) *Serial Shipping Container Code (SSCC)*

*e.g. 1<sup>st</sup> Barcode: (02)1 8901072 00253 4 (17) 180815 (10) RNBXY0514 (37)5000*  
*2<sup>nd</sup> Barcode :(00) 1 8901072 001234567 6*

Attribute	Description	Length	Nature	Data Type
(02)	<i>Application Identifier to indicate GTIN-14 Brackets not encoded in the</i>	2	<i>Fixed</i>	<i>Numeric</i>

	<i>barcode</i>			
<i>1 8901072 00253 6</i>	<i>Unique Product Number-GTIN-14</i>	<i>14</i>	<i>Fixed</i>	<i>Numeric</i>
<i>(17)</i>	<i>Application Identifier to indicate Expiry date Brackets not encoded in the barcode</i>	<i>2</i>	<i>Fixed</i>	<i>Numeric</i>
<i>180815</i>	<i>Expiry Date in YYMMDD format</i>	<i>6</i>	<i>Fixed</i>	<i>Date</i>
<i>(10)</i>	<i>Application identifier to indicate Lot/batch number  Brackets not encoded in the barcode</i>	<i>2</i>	<i>Fixed</i>	<i>Numeric</i>
<i>RNBXY0514</i>	<i>Batch No / Lot No</i>	<i>20</i>	<i>Variable</i>	<i>Alphanumeric</i>
<i>(37)</i>	<i>Application identifier to indicate Quantity in Outer Carton</i>	<i>2</i>	<i>Fixed</i>	<i>Numeric</i>
<i>5000</i>	<i>Quantity/no of units</i>	<i>Upto 8</i>	<i>Variable</i>	<i>Numeric</i>
<i>(00)</i>	<i>Application identifier to indicate the SSCC Brackets not encoded in the barcode</i>	<i>2</i>	<i>Fixed</i>	<i>Numeric</i>
<i>1 8901072 001234567 6</i>	<i>Unique number of the tertiary pack</i>	<i>18</i>	<i>Fixed</i>	<i>Numeric</i>
<i>Recommended Barcode – GS-128</i>				



	To,  Warehouse-BPPI, Gurgaon Haryana	Mnfd By,  AAA Pharma Company 125, SEZ  Ahmedabad-382213 Gujrat
	Drug Name: Dobucin 500 mg Exp Date: 15 Aug 2018 Batch No: RNBXY0514   (02) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (37) 5000   (00) 1 8901072 001234567 6	

**Secondary Level Pack: Data Attributes Captured**


- Unique product identification code (GTIN)
- Expiry date
- Batch No.
- Qty

*e.g. Barcode - (02) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (37) 500*

Attribute	Description	Length	Nature	Data Type
(02)	Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode	2	Fixed	Numeric
1 8901072 00253 6	GTIN-14- Unique product code with first digit being the packaging indicator	14	Fixed	Numeric
(17)	Application Identifier to	2	Fixed	Numeric

	<i>indicate Expiry date</i>  <i>Brackets not encoded in the barcode</i>			
180815	<i>Expiry Date in YYMMDD format</i>	6	<i>Fixed</i>	<i>Date</i>
(10)	<i>Application identifier to indicate Lot/batch</i>  <i>Brackets not encoded in the barcode</i>	2	<i>Fixed</i>	<i>Numeric</i>
RNBXY0514	<i>Batch No / Lot No</i>	<i>Upto 20</i>	<i>Variable</i>	<i>Alphanumeric</i>
(37)	<i>Application Identifier to indicate serial number</i>  <i>Brackets not encoded in the barcode</i>	2	<i>Fixed</i>	<i>Numeric</i>
500	<i>Quantity/Units in Secondary pack</i>	<i>Upto 8</i>	<i>Variable</i>	<i>Alphanumeric</i>
<i>Recommended Barcode depending upon the space available – GS1 Data matrix</i>  <i>Or</i>  <i>GS1-128</i>	<div style="text-align: center;">   (02) 1 8901072 00253 6  (17) 180815  (10) RNBXY0514  (37) 500    <i>or</i>    (02) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (37) 500 </div>			

**Primary Level Pack: Data Attributes Captured**

<i>a. Unique product identification code (GTIN)</i>				
<b>Barcode e.g. - (01) 1 8901072 00253 6</b>				
<b>Attribute</b>	<b>Description</b>	<b>Length</b>	<b>Nature</b>	<b>Data Type</b>
(01)	<i>Application Identifier to indicate GTIN-14 Brackets not encoded in the barcode</i>	2	Fixed	Numeric
1 8901072 00253 6	<i>GTIN-14 with first digit being the packaging indicator</i>	14	Fixed	Numeric
<i>Recommended Barcode – GS1 Datamatrix,</i>	 (01) 1 8901072 00253 6			

**Please contact GS1 India office for any further assistance –**

**GS1 India**

(Under Min. of Commerce, Govt. of India)

330, 2<sup>nd</sup> Floor, ‘C’ Wing, August Kranti Bhawan,

Bhikaji Cama Place, New Delhi - 110066

**T** +91-11-42890890, (D) +91-11-42890846

**F** +91-11-26168730

**E** [ankit@gs1india.org](mailto:ankit@gs1india.org)

**W** <http://www.gs1india.org>



**ANNEXURE-II**  
{ Clause 4.1(a)(i)}

**MANUFACTURER'S AGREEMENT WITH MARKETER**

To  
The CEO  
Bureau of Pharma PSUs of India,  
IDPL corporate office Complex, Old Delhi-Gurgaon Road,  
Dundahera, Gurgaon- 122016 (Haryana) ,

Dear Sir,

1. We ----- who are established and reputable manufacturer of Drugs having factory/factories at -----and hereby declare that we do not market our products. Therefore, we authorize M/S ----- (Name and address) to bid, negotiate and contract with your tender No. BPPI/Drug-050/2017 dated 22/05/2017 for supply of drugs manufactured by us.
2. No company of the firm or individual other than M/S ----- authorised to bid, negotiate and conclude the contract in regard to this business against this specific tender as also for a business in the entire territory of India.
3. This agreement is valid from -----to -----(This period will be the date of opening tender till valid one year shelf life of the drugs or period of contract/ price agreement whichever is more.
4. The ex-factory cost of the Drugs being quoted will be provided by us whenever called for. We also undertake that we will not quote a price higher than supplied to any institute in last 6 months. In case our submission is found wrong, we undertake to be liable for punitive action in the form of recovery of excess amount/ withholding of payment/ any other action as deemed appropriate by department.
5. An marketing commission of-----% is included in the gross ex-works price is applicable of  
  
M/s-----
6. We hereby extend our full guarantee and warrantee as per relevant conditions of contract for the goods offered for supply against this invitation for bid by the above firm. In the event of failure by authorized marketer in honouring the contract, we undertake to provide remedial action at the earliest without any additional charges.
7. Our other responsibilities include.

i. Provision of requisite inspection and testing facilities at our works in respect of supply order placed on our agent.

ii. -----

{Here specify in detail manufacturers responsibilities}

The services to be rendered by the marketer, M/s-----  
are as under:-

i. -----

ii. -----

{Here specify the services to be rendered by the agent}

8. We certify that neither we, nor our agent is blacklisted/ debarred/de-registered/banned by any Govt. agency.

9. We jointly agree to abide by the following clauses in the contract:

- a) Penalty for use of undue influence.
- b) Access to books of accounts.

10. We undertake that CST/ VAT registration number, Permanent Account Number (PAN), last three years Bank Statement of Accounts, Banker details of our authorized agent/ distributor will be provided as and when demanded by the department.

Yours faithfully,

(Name, Signature & Stamp)

(Name, Signature & Stamp)

(Name of Authorized Marketer)

(Name of Manufacturer)

Date:

Date:

NOTE: THIS LETTER OF AUTHORIZATION SHOULD BE ON THE ORIGINAL LETTER HEAD OF THE MANUFACTURING CONCERN AND SHOULD BE INK SIGNED BY BOTH THE ORIGINAL MANUFACTURERE & THE AUTHORIZED MARKETER, BY A PERSON WHO IS COMPETENT AND HAVING THE POWER OF ATTORNEY TO BID THE MANUFCTURER, A COPY OF NOTARIZED POWER OF ATTORNEY SHOULD ALSO BE FURNISHED, NAME, SIGNATURE AND OFFICAL STAMP OF MANUFACTURER AND MARKETER TO BE APPENDED.

### **ANNEXURE –III**

Ref. Clause No. 4.1(a)(ii)

### **DECLARATION**

**(NOTE:-In case Bid is submitted by the Marketer, this declaration is to be signed by Marketer as well as Manufacturer)**

I/We M/s. .... represented by its Proprietor/Managing Partner /Managing Director having its registered office at .....and its factory premises at .....do hereby declare as under:-

(I) that I/we have carefully read all the terms and conditions of tender in ref. no. **BPPI/DRUG-050/2017 Dtd. 22/05/2017** including Amendment(s) to Tender document (if any) issued by Bureau of pharma public sector undertakings of INDIA, GURGAON, 122016 and accept unconditionally all terms and condition of tender document including Amendment(s) to Tender document (if any).

(II) that I/We are holding and have uploaded (a) valid drug license for quoted drugs,(b) valid WHO-GMP certificate , (c) 2 years market standing certificate for quoted products issued by licensing authority for quoted drugs, (d) a certificate manufactured & marketed two batches within 3 years issued by C.A. for quoted drugs, (e ) valid non conviction certificate not older than 6 months,(f) Valid Import license (If applicable) and also enclosed all undertaking/declaration as per Annexure mentioned in the tender document. . On the basis of such undertaking, the price bid shall be opened within a week after opening of technical bid. However, any document uploaded with technical bid is not complying as per undertaking, the contract/agreement shall be cancelled with forfeiture of EMD/SECURITY DEPOSIT/Bank guarantee against tender no. BPPI/DRUG-050/2017 Dtd. 22/05/2017 along with other action.

(III) I/We declare that we possess the valid drug manufacturing licence and WHO-GMP(World Health Organisation-Good Manufacturing Practices) Certificate issued by competent authority and complies and continue to comply with the condition lied in schedule M of Drug & cosmetic act, 1940 the rules made there under.

I am / We are aware of the Tender inviting Authority's right to forfeit the Earnest Money Deposit and /or Security Deposit and blacklist me/us for a period of 5 years if,any information furnished by us proved to be false at time the of inspection and not complying the condition as per schedule M of the said Act for a period of five years.

(IV) (a) I do hereby declare that I will supply the drug with bar code as per ANNEXURE I and as per the design as per enclosures to ANNEXURE XIV enclosed with tender document as well as other instruction given in this regard.

(b) Further, I / we do hereby declare that I will supply the drugs by affixing logo on Primary/Secondary/ Tertiary packing for the imported items along with the generic name

as per the designs given in enclosures to Annexure XIV A as well as other instructions given in this regard.

(V) that in pursuant to the conditions in Clause No. 7.2 of the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

(VI) that our company/applied items have not been blacklisted/debarred/de-registered/banned due to quality failure of the drugs supplied either by any State government or Central Government Organization or its drug procurement agencies for the following products quoted in the tender at the time of submission of bid. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies during last three years. We are eligible to participate in the tender ref. No. **BPPI/DRUG-050/2017 Dtd. 22/05/2017** for the following products:-

S. No.	Drug Code	Name of the Drug

Signed.....

Name

Designation

(Company Seal)

Witness:-(1).....

(2).....

To be attested by the Notary

## **ANNEXURE-IV**

Ref. Clause No. 7.1 & 3(ii)

### **DETAILS OF E.M.D SUBMITTED**

UPLOAD THE SCANNED COPY OF DRAFT/ PAY ORDER/BANK GURANTEE

**ANNEXURE -VI**

**Ref. Clause No. 4.1{f(ii)}**

**ANNUAL TURNOVER STATEMENT**

The annual Turnover of M/s. ....for the past three years are given below and certified that the statement is true and correct.

Sl.No.	Financial Year	Turnover in Lakhs(Rs.)
1.	2013-14	
2.	2014-15	
3.	2015-16	
<b>TOTAL</b>		Rs.....Lakhs
<b>Average Turnover per annual</b>		Rs.....Lakhs

Date:

Signature of Auditor/Chartered Account

Seal:

(Name in Capital)

Registration no.

## **ANNEXURE-V A**

**Ref. Clause No. 4.1 (f)(i)**

**(Format for a certificate** from the C.A.(Chartered Accountant) or ICWA)

It is certified that M/s \_\_\_\_\_ has Financial capacity to manufacture and deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender. This certificate is based on their Manufacturing capacity, inventory of raw Material and financial statement.

Date

(Name, Signature & Stamp)  
Registration no.



**ANNEXURE -VI**

**Ref. Clause No. 4.1{f(ii)}**

**[Format for a certificate for investment from the C.A.(Chartered Accountant)]**

It is certified that M/S ..... (Name of company and address)  
having factory at .....(address of factory) have  
invested Rs 10 crores or above for installation of plant and machinery excluding cost  
towards land, building & other infrastructure to manufacture the drugs. It is also certified  
that the statement is true and correct.

Date:

Signature of Auditor/Chartered Account

Seal:

(Name in Capital)

Registration no.

**ANNEXURE – VII**

**Ref. clause 4.1 (q)**

**LIST OF ITEMS QUOTED**

Sl.No.	Details																			
1.	Name of the firm and address (As given in Drug licence)																			
2.	Drug Licence No. in form 25 & 28 Or import Licence No.																			
3.	Date of issue & validity																			
4.	WHO-GMP(World Health Organisation-Good Manufacturing Practices) Certificate obtained on																			
5.	Non-conviction Certificate Obtained on																			
6.	Market standing Certificate Obtained on																			
7.	Details of Endorsement for all products quoted:																			
<table border="1" style="width: 100%; border-collapse: collapse;"><thead><tr><th style="width: 10%;">Sl.No.</th><th style="width: 10%;">Drug Code</th><th style="width: 20%;">Drug Name</th><th style="width: 20%;">Specifications IP/BP/USP</th><th style="width: 20%;">Date of Endorsement obtained from the State Drugs Controller</th><th style="width: 20%;">Whether Endorsement is in Generic or Trade Name</th></tr></thead><tbody><tr><td>1.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2.</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>			Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name	1.						2.					
Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name															
1.																				
2.																				
<b>Authorised signatory:</b> <b>Date:</b>																				

## ANNEXURE – VIII

Ref. Clause 4.1 (r)

### CHECK-LIST( Whether Uploaded the documents)

#### COVER – A

S.No.	Check List	YES	NO
1.	Checklist - ANNEXURE – VII		
2.	EMD Rs.100,000/- in the form of <b>Bank Guarantee or Bankers Cheque or Demand Draft</b> uploaded as per ANNEXURE-IV DD No.....Dated.....issued by .....(name of bank) and <b>delivered to BPPI</b> . Uploaded NSIC certificate for exemption if any.		
3.	Documentary evidence for the constitutions of the company / concern		
4.	Scanned copy of License for the Product duly approved by the Licensing Authority for each and every product quoted		
5.	Scanned copy of Import License, if Imported and whole sale Drug license		
6.	COPP certificate as per WHO format of their Principal Manufacturing company, if imported		
7.	The instruments such as power of attorney, Resolution of board etc.,		
8.	Authorization letter nominating a responsible Person of the tenderer to transact the business with the Tender inviting Authority		
9.	Scanned copy of Market Standing Certificate issued by the Licensing Authority		
10.	A certificate from their C.A.or ICWA that manufactured at least 2 commercial batch in last three years.		
11.	Scanned copy of WHO-GMP(World Health Organisation-Good Manufacturing Practices) Certificate		
12.	Scanned copy of Non Conviction Certificate issued by the licensing authority not older than 6 months.		
13.	Scanned copy of Latest Sales Tax Clearance Certificate/returns filed.		
14.	Scanned copy of Latest income tax assessment orders/returns filed.		
15.	Copies of Bio- equivalence studies for quoted drugs from DGI approved centres/ laboratories, if any		
16.	Scanned copy of ANNEXURE-II (Agreement with Manufacturer) if any , <b>original Annexure I delivered to BPPI</b> .		
17.	Scanned copy of ANNEXURE –III (Declaration for eligibility in participating the tender) and <b>original Annexure II delivered to BPPI</b> .		
18.	Scanned copy of ANNEXURE V{certificate from the		

	C.A.(Chartered Accountant) or ICWA that the bidder has Production & financial capacity} and <b>original certificate delivered to BPPI.</b>		
18A	Scanned copy of ANNEXURE V A in case of importer{certificate from the C.A.(Chartered Accountant) or ICWA that the bidder has financial capacity} and <b>original certificate delivered to BPPI.</b>		
19.	Scanned copy of ANNEXURE -VI (A certificate from CA for Annual Turnover Statement)		
20.	Scanned copy of ANNEXURE - VII(List of Items quoted without rates) .		
21.	Scanned copy of ANNEXURE-XI (Details for Manufacturing Capacity & Batch Size)		
22.	Scanned copy of ANNEXURE—XV (Mandate form)		

**NOTE:- EMD instrument, ANNEXURE II (if applicable) , ANNEXURE III and ANNEXURE V {a certificate from the C.A.(Chartered Accountant) or ICWA that the bidder has Production & financial capacity} or ANNEXURE V in case of impoter {a certificate from the C.A.(Chartered Accountant) or ICWA that the bidder has financial capacity} are to be delivered in original to BPPI, Gurgaon on or before ‘ Bid Submission End Date ’.**

Name and signature of authorised signatory (with company seal)

.....

## Annexure -IX

### Clause 8.1 &8.2

**Bureau of Pharma Public Sector Undertakings of India, Gurgaon**  
**Tender for supply of drugs (Tender No. BPPI/DRUG-50/2017 Dtd. 16/05/2017)**

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Medicines	Unit Size	Pack Size	Packing per Carton (Shipper Pack)	Tender quantity in units size
1	1	Aceclofenac + Paracetamol (100 mg + 325 mg) Tablets	10's	10'sX10	10'sX10X10	1,000,000
2	2	Aceclofenac 100 mg Tablets IP	10's	10'sX10	10'sX10X10	600,000
3	4	Acetaminophen + Tramadol Hydrochloride (325 mg + 37.5 mg) film coated Tablets	10's	10'sX10	10'sX10X10	600,000
4	5	ASPIRIN Tablets IP 150 mg	14's	14's x 10	(14's X 10 x10) X 10	2,500,000
5	6	DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ CHLORZOXAZONE 500 mg Tablets	10's	10's x 10	(10's X 10 x10) X 10	550,000
6	7	Diclofenac Gel( Diclofenec Diethylamine 1.16 % w/w) BP	15 g	15gX 20	15gX 20X10	500,000
7	8	Diclofenac Sodium + Serratiopeptidase (50mg + 10mg) Tab	10's	10's x10	(10's x 10 x 10) x 20	197000
8	10	Diclofenac Sodium 25mg per ml Inj. IP	3 ml	10X3ml	100x10x3ml	500,000
9	11	Diclofenac Sodium 50 mg Tab IP	10's	10's x 10	10'sX10X10	1,000,000
10	12	Etoricoxib 120mg Tab IP	10's	10's x 10	10'sX10X10	245,000
11	13	Etoricoxib 90mg Tab IP	10's	10'S X 10	10'S X 10X10	337,000
12	14	Ibuprofen 400mg + Paracetamol 325mg Tablets	15's	15'sx10	(15'sx10x10)x 5	2,000,000

13	16	Ibuprofen Tablets IP 400mg	15's	15's x 10	(15's x10x10)x 10	2,000,000
14	20	Nimesulide 100 mg Tab IP	10's	10'S X 10	10'S X 10X10	360,000
15	21	Paracetamol + Diclofenac Sodium (325 mg + 50 mg) Tab	10's	10'S X 10	10'S X 10X10	654,000
16	22	Paracetamol 125 mg / 5 ml Syrup IP	60 ml bottles	1'sX 10'S	1'sX10X10	500,000
17	23	Paracetamol 500mg Tab IP	10's	10'S X 10	10'S X 10X10	2,677,000
18	25	Serratiopeptidase Tablets 10 mg	10's	10'S X 10	10'S X 10X10	338,000
19	26	Tramadol Hydrochloride 50mg/ml Inj.	2ml	2mlX 10	50x10x2ml	84,000
20	27	Tramadol Hydrochloride 50mg/ml Inj.	1ml	1mlX 10	1mlX10X50	53,000
21	28	Tramadol Hydrochloride 50 mg Tab	10's	10'sX10	10'sX10X10	158,000
22	30	Amikacin Sulphate 50mg/ml inj. IP	2ml Vial	2ml x 20	2mlx20x50	142,000
23	31	Amikacin 250mg/2ml inj. IP	2ml Vial	2ml x 20	2mlx20x50	300,000
24	32	Amikacin 250mg/ml inj. IP	2ml Vial	2ml x 20	2mlx20x50	300,000
25	35	Amoxycillin + Clavulanic acid (1000 mg + 200mg) Powder for Injection IP	Vial with 10 ml WFI	(vial x 10)	(vial x 10) x 50	100,000
26	36	Amoxycillin + Clavulanic acid (200 mg+28.5 mg /5ml) Powder for suspension IP	30 ml bottles	2x30 ml	2x30 mlX50	100,000
27	37	Amoxycillin + Clavulanic acid (250 mg + 50 mg) Powder for injection IP	Vial with 10 ml WFI	1x10 ml	30x10 ml	50,000
28	40	AMOXYCILLIN 250 mg+ CLOXACILLIN 250 mg Capsules	10's	10's x 10	10's x 10 X10	193,000
29	42	Amoxycillin 125 mg Kid Tabs IP	10's	10's x 10	10'sx10x100	200,000

30	46	Ampicillin Injections I.P. 500mg	Vial & WFI	vial x 25	(vial x 25) x20	100,000
31	53	Cefixime Oral Suspension IP 50 mg/5 ml	30 ml bottle	1'sx10	1'sx10x20	100,000
32	54	Cefixime 100mg film coated Tablets IP	10's	10'sX10	10'sX10X10	60,000
33	55	Cefixime 200mg film coated Tablets IP	10's	10'sX10	10'sX10X10	500,000
34	56	Cefoperazone + Sulbactam ( 1g + 1g) Inj. IP	Vial & wfi	1'sx10	1'sx10x20	100,000
35	57	Cefoperazone + Sulbactam (500 mg + 500 mg) Inj.	Vial & wfi	1'sx10	1'sx10x20	100,000
36	58	Cefoperazone 1 gm Inj. IP	Vial	1's x 10	1's x 10 x 10	65,000
37	59	Cefotaxime Sodium & Sulbactam Sodium (1g + 500 mg) Inj.	Vial & wfi	1's x10	1's x10 x 20	100,000
38	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	VIAL & WFI	1's x10	1's x10 x 20	58,000
39	62	Cefotaxime Sodium Injections IP 1000mg	Vial & wfi	vial x 10	(vial x 10) x 50	140,000
40	63	Cefotaxime Sodium Injections IP 250mg	Vial & wfi	vial x 10	(vial x 10) x 50)	177,000
41	64	Cefotaxime Sodium Injections IP 500mg	2ml Vial & wfi	vial x 10	(vial x 10) x 50	196,000
42	65	Cefpodoxime 100 mg DT IP	10's	10X10's	10'sX10X10	91,000
43	70	Ceftriaxone + Sulbactam (1000 mg + 500 mg) Inj.	Vial & wfi	1's x 10	1's x 10 x 10	65,000
44	71	Ceftriaxone + Tazobactam 1000 mg + 125 mg Inj.	Vial & wfi	1's x 10	1's x 10 x 10	100,000
45	73	Ceftriaxone +Sulbactam (250 mg + 125 mg) injection	Vial & wfi	1's x 10	1's x 10 x 10	100,000
46	75	Ceftriaxone Injections IP 1 g	5ml Vial & WFI	vial x 10	(vial x 10) x 50)	195000
47	76	Ceftriaxone 250 mg Inj. IP	Vial & wfi	vial x 10	(vial x 10) x 50)	100,000

48	78	Cefuroxime Axetil 250 mg film coated Tablets IP	10's	10'sX10	10'sX10X10	250,000
49	79	Cefuroxime Axetil 500mg film coated Tablets IP	10's	10'sX10	10'Sx10x10	300,000
50	80	Cephalexin 125 mg Dispersible Tablet IP	10's	10'sX10	10'sX10X10	100,000
51	81	Cephalexin 250 mg Caps IP	10's	10'sX10	10'sX10X10	175,000
52	82	Cephalexin 500 mg Caps IP	10's	10'sx10	10'sx10x100	1,00,000
53	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG FILM COATED TABLETS	10's	10'sX10	10'sX10X10	250,000
54	84	Ciprofloxacin + Tinidazole (500 mg + 600 mg) film coated Tablets	10's	10'S X 10	10'S X 10X10	287,000
55	87	Clotrimazole 1% w/w ointment IP	15 g tubes	1'S X 20	1'S X 20X10	400,000
56	95	Levofloxacin 250 mg film coated Tablets IP	10's	10'sX10	10'sX10X10	300,000
57	96	Levofloxacin 500 mg film coated Tablets IP	10's	10'sX10	10'sX10X10	300,000
58	97	Meropenem 1gm Inj. IP	Vial & wfi	1'S X 10	1'S X 10X 10	100,000
59	98	NORFLOXACIN 400 mg + TINIDAZOLE 600 mg FILM COATED Tablets	10's	10'sX10	10'sX10X10	500,000
60	100	Ofloxacin + Ornidazole (200 mg + 500 mg) film coated Tablets	10's	10'sX10	10'sX10X10	700,000
61	101	Ofloxacin 200 mg film coated Tablets IP	10's	10'sX10	10'sX10X10	500,000
62	102	Ofloxacin 400 mg film coated Tablets IP	10's	10'sX10	10'sX10X10	500,000
63	103	Piperacillin + Tazobactam 4 g + 0.5 mg Injections	Vial & wfi	1 vial x 10	(1vial x 10) x 50)	50,000
64	105	Roxithromycin 150 mg film coated Tablets IP	10's	10'sX10	10'sX10X10	100,000
65	107	Tinidazole 300 mg film coated Tablets	10's	10's x10	(10'sx10x10) x 10	19000



66	108	Tinidazole 500 mg film coated Tablets IP	10's	10'sX10	10'sX10X10	1,500,000
67	109	VANCOMYCIN INTRAVENOUS INFUSION IP 500 mg	Vial &WFI	1's x 10	1's x 10 x50	50,000
68	110	Adapalene 0.1 % w/v Gel	15G Tube	1's x10	(1's x10)x100	16000
69	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM	15gm X 20	15gm X 20 X20	900,000
70	115	Calamine lotion 100 ml	100ml bottle	100 ml X 6	100 ml X 6 X20	271,000
71	117	CHLORHEXIDINE MOUTHWASH IP 0.2 % w/v	100 ml	100 ml X 6	100 ml X 6 X20	380,000
72	125	Povidone Iodine 5%w/w Ointment USP	15 gm tubes	1's x 20	1's x 20 x 10	500,000
73	127	Povidone Iodine 5% Solution 100ml	100ml bottle	100 ml X 6	100 ml X 6 X20	156,000
74	128	Povidone Iodine 5 % Solution IP	500 ml bottles	1's x 10	1's x 10 x 5	20,000
75	129	Povidone Iodine 7.5% Solution IP	500 ml bottles	1's x 10	1's x 10 x 5	20,000
76	130	(Chlorhexidine + Cetramide ) (1.5 % w/v + 3% w/v) Solution	100 ml bottles	1's x 10	1's x 10 x 10	100,000
77	133	Glibenclamide 2.5 mg Tabs IP	10's	10X10	10X10X200	86000
78	134	Glibenclamide 5 mg Tabs IP	10's	10X10	10X10X200	304000
79	135	Gliclazide 40 mg Tabs IP	10's	10'sX10	10'sX10X200	1,000,000
80	136	Gliclazide 80 mg Tabs IP	10's	10'sX10	10'sX10X200	1,000,000
81	137	Glimeperide 1mg Tab IP	10's	10'sX10	10'sX10X200	3,000,000
82	138	Glimeperide 2mg Tabs IP	10's	10'sX10	10'sX10X200	3,000,000
83	142	INSULIN INJECTION IP 40 IU/ml (Insulin Human Recombinant)	10 ml Vial	10 ml Vial X10	10 ml x 10 x 20	150,000

84	144	METFORMIN HYDROCHLORIDE SUSTAIN RELEASE TABLETS IP 1000 MG	10's	10'sX10	10X10X50	2,500,000
85	145	Metformin Hydrochloride 500mg Tabs IP	10's	10'sX10	10'sX10X100	5,700,000
86	153	CISPLATIN INJECTION IP 10 MG	VIAL & WFI	1's x 20	1's x 20 X10	7,000
87	155	Doxorubicin 10 mg Inj. IP	Vial	1 x10's	1 x10's x20	20,000
88	156	Doxorubicin 50 mg Inj. IP	Vial	1 x10's	1 x10's x 20	5,000
89	159	Gemcitabine 1000 mg Inj. IP	Vial	1 x10's	1 x10's x 20	2,000
90	160	Gemcitabine 200 mg Inj. IP	Vial	1 x10's	1 x10's x 20	5,000
91	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ml	1X 10'S	100ml X 20	150,000
92	170	MANNITOL INJECTION IP 20% w/v	100 ml	100 ml X 6	100 ml X 6 X20	89,000
93	172	METRONIDAZOLE INJECTION IP 5 mg / ml	100 ml	(100ml x 10)	(10X100 ML) x10	300,000
94	177	Albendazole (200 mg/ 5ml) Syrup IP	10 ml bottles	10 ml x 10	10 ml x 10 x 20	267,000
95	178	ALBENDAZOLE 400 mg + IVERMECTIN 6 mg Tablets	1's	1's X10	1's X10 X10	500,000
96	180	Bisacodyl 5mg Tablets IP	10's	10'sX10	10'sX10X10	600,000
97	181	TRICHOLINE CITRATE 275 mg+ CYPROHEPTADINE HCl 2 mg/5ml SYRUP	200 ml	1'S X 10	1'S X 10 X 10	150,000
98	183	Dicyclomine 10 mg Tabs IP	10's	10'sX10	10'sX10X10	250,000
99	184	Dicyclomine HCL + Paracetamol (20mg + 325 mg) Tablets	10's	10's x10	(10's x10x10) x 10	723000
100	186	Domperidone Tablets IP 10 mg	10's	10's x10	(10's x 10x 10)x10	155000
101	187	Domperidone 5 mg. / 5 ml Syrup IP	30 ml bottles	1'S X 10	1'S X 10 X 10	100,000

102	188	ANTACID Tablets [DRIED Al(OH) <sub>3</sub> + Mg(OH) <sub>2</sub> + SIMETHICONE (250mg + 250mg + 50mg)	10's	10'sX10	10'sX10 X100	300,000
103	191	FAMOTIDINE TABLETS IP 20 MG	14's	14's x 10	14's x 10X 100	300,000
104	192	FAMOTIDINE TABLETS IP 40 MG	14's	14's x 10	14's x 10X 100	240,000
105	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's	10'sx10	(10'sx10x10) x10	300,000
106	197	Lactulose Syrup 10 gm/ 15 ml	100 ml bottle	100 ml X 6	100 ml X 6 X 5	211,000
107	198	Aluminium Hydroxide + Magnesium Hydroxide (250+250mg / 5ml) Suspension	170 ml	170ML X 10	170 ml x 10 X 5	267,000
108	199	Metoclopramide 10 mg Tabs IP	10's	10'sx10	10'Sx10x50	200,000
109	203	Misoprostol 200 mcg film coated Tablets IP	4's	4's x 10	4's x 10 x 100	119,000
110	206	Omeprazole + Domperidone (20 mg + 10 mg) Caps	10's	10'sx10	10'sX10X10	1,693,000
111	207	Omeprazole 20 mg capsules IP	10's	10'sx10	10'sX10X10	2,722,000
112	208	ONDANSETRON INJECTION IP 2 mg/ml	2 ML	2ml x10	(2X10)X10x15	616,000
113	209	Ondansetron 4 mg Tabs IP	10's	10'sx10	10'sX10X200	802,000
114	210	Ornidazole 500 mg film coated Tablets IP	10's	10'sx10	10'sX10X100	500,000
115	212	Pantoprazole 40 mg enteric coated Tablets IP	10's	10'sx10	10'sX10X10	5,041,000
116	213	Pantoprazole 40mg Inj.	vial	1 x10's	1 x10's x 20	300,000
117	214	Rabeprazole + Domperidone SR (20 mg + 30 mg)caps.	10's	10'sx10	10'sX10X10	3,302,000
118	215	Rabeprazole 20 mg enteric coated Tablets IP	10's	10'sx10	10'sX10X10	2,443,000
119	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML	2mlx10	(2X10)X10x15	1,137,000
120	218	RANITIDINE Tablets IP 300 mg	10's	10'sX10	10'sX10X10	791,000

		FILM COATED				
121	220	Calcium Carbonate 500mg + Vitamin D3 250 IU Tablets film coated	10's	10x10	100 X 10X10's	642000
122	223	PYRIDOXINE HCl 10 mg+ DOXYLAMINE 10 mg + FOLIC ACID 2.5 mg Tablets	30's	30's x 10	(30's x10)x100	285,000
123	224	Folic Acid 5mg Tablet 10's	15's	15'sx10	15'sx10x100	2,406,000
124	225	Iron(eq. to elemental iron 50mg) + Folic Acid(0.5mg) /15ml Syrup	200 ml bottles	1's x 10	1's x 10 x 5	300,000
125	227	Polyvitamin (Prophylactic) NFI film coated Tablets	10's	10'sX10	10'sX10X10	200,000
126	229	Haematinic Syrup of Iron , acid and Vitamin B12 100ml	100ml bottle	100 ml X 6	100 ml X 6 X20	100,000
127	230	VITAMIN B COMPLEX (B1,B2,B6,B12) & VIT. C WITH ZINC 22.5 MG CAPSULES	10's	10'sX10	10'sX10X200	4,299,000
128	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's	10'sX10	10'sX10X10	500,000
129	232	VITAMIN B-VOMPLEX Syrup NFI	200 ML	1's x 10	1's x 10 x 5	136,000
130	235	BUDESONIDE RESPULES 0.5 MG	2 ML	2mlx10	(2X10)X10x15	150,000
131	239	Cetirizine (5 mg/ 5 ml) Syrup IP	60 ml bottles	1's x 10	1's x 10 x 20	146,000
132	240	Cetirizine 10mg film coated Tablets IP	10's	10'sX10	10X10X10	250,000
133	243	COUGH SYRUP [DIPHEN.14 mg. + AMMONIUM CHL.135 mg. + SOD.CIT.57 mg. + MENTHOL 0.9 mg/5ml]	110 ml	110ml X 25	110ml X 25X10	200,000
134	244	Theophylline 25.3 mg+ Etophylline 84.7mg /2ml Injections	2ml	2ml x 10	(2mlx10x10) x 10	170000
135	246	Fexofenadine 120 mg film coated Tablets IP	10's	10'sX10	10X10X10	268,000

136	247	Fexofenadine 180 mg film coated Tablets IP	10's	10'sX10	10'sX10X100	136,000
137	248	Levocetirizine 5 mg film coated Tablets IP	10's	10'sX10	10'sX10X100	331,000
138	250	Montelukast Sodium 5 mg Tab IP	10's	10'sX10	10'sX10X100	300,000
139	251	Montelukast Sodium 10 mg Tab IP	10's	10'sX10	10'sX10X100	500,000
140	252	Montelukast Sodium + Levocetirizine (10 mg + 5mg) film coated Tablets	10's	10'sX10	10'sX10X100	1,110,000
141	253	PHENIRAMINE Tablets IP 25 mg	15's	15's x 10	15's x 10 X200	242,000
142	256	SALBUTAMOL Tablets IP 2 MG	10's	10's x 10	10's x 10 X100	150,000
143	260	Salbutamol Tablets IP 4mg	10's	10x10	100 X 10X10's	401000
144	263	Amlodipine + Atenolol (5 mg + 50 mg) film coated Tablets	10's	10'sX10	10X10X10	4,152,000
145	264	Amlodipine 5mg Tablets IP	10's	10'sX10	10X10X100	5,000,000
146	265	Atenolol 50 mg Tabs IP	14's	10X14	14X10X100	2,618,000
147	266	Atorvastatin 10mg film coated Tablets IP	10's	10'sX10	10X10X200	5,581,000
148	267	Atorvastatin 20 mg film coated Tablets IP	10's	10'sX10	10X10X200	3,882,000
149	269	Clopidogrel 75mg Tabs IP	10's	10'sX10	10X10X100	2,300,000
150	270	ASPIRIN 75 mg + CLOPIDOGREL 75 mg Tablets	10's	10'sX10	10X10X100	1,856,000
151	273	Dobutamine 250 mg/ 20ml Inj. IP	Vial	20 ml x 10	20 ml x 10 x 10	50,000
152	275	Enalapril Tablets I.P. 5mg	10's	10X10	10X10X200	154000
153	276	Enoxaparin 40 mg/0.4 ml Inj. IP	0.4 ml	0.4 ml x 10	0.4 ml x 10 x 100	50,000
154	277	Enoxaparin 60 mg/0.6 ml Inj. IP	0.6 ml	0.6 ml x 10	0.6 ml x 10 x 100	100,000

155	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML	2mlx10	(2X10)X10x15	525,000
156	279	Frusemide 40 mg Tabs IP	10's	10'sX10	10X10X200	832,000
157	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's	15's x 10	15's x 10 X200	500,000
158	286	Lisinopril 5mg Tabs IP	10's	10'sX10	10X10X200	300,000
159	287	Losartan + H.Ch. Thaizide (50 mg + 12.5mg) film coated Tablets IP	10's	10'sX10	10X10X100	1,526,000
160	288	Losartan 25mg film coated Tablets IP	10's	10'sX10	10X10X100	2,094,000
161	290	Metoprolol 25 mg Tabs IP	10's	10'sX10	10X10X200	2,161,000
162	291	Metoprolol 50 mg Tabs IP	10's	10'sX10	10X10X200	815,000
163	293	Ramipril 2.5 mg Tabs IP	10's	10'sX10	10X10X200	1,000,000
164	294	Ramipril 5 mg Tabs IP	10's	10'sX10	10X10X200	1,200,000
165	298	Telmisartan + Hydrochlorthiazide (40 mg + 12.5 mg ) Tabs	10's	10'sX10	10X10X100	1,971,000
166	299	TELMISARTAN Tablets IP 20 mg	10's	10'sX10	10X10X200	3,715,000
167	300	Telmisartan 40 mg Tabs IP	10's	10'sX10	10X10X100	3,858,000
168	301	Tranexamic Acid 500 mg Tabs IP	10's	10'sX10	10X10X10	100,000
169	302	TRANEXAMIC ACID 100 MG/ ML injection	5 ML	1's x10	(5x10x10)x10	100,000
170	304	Arteether 150mg/2ml inj IP	2ml Vial	2ml x 10	2ml x 10 x 100	61,000
171	305	Chloroquine Phosphate 250 mg film coated Tablets	10's	10's x10	(10's x 10x10)x10	419000
172	306	PRIMAQUINE TABLETS IP 15 MG	10's	10'sX10	10'sX 10X 100	54,000
173	311	Disodium hydrogen Citrate (Alkalyser) 1.4 mg/5ml Syrup	100 ml bottles	1's x 10	1's x 10 x 10	156,000
174	312	Oral Rehydration Salts Citrate IP 21 GM (WHO Formula) Sachet IP	1S	21.5 gm x 10	21.5 gm x 10 x 30	1,920,000

175	313	Alprazolam 0.25 mg film coated Tablets IP	10's	10'sX10	10X10X10	1,090,000
176	314	Alprazolam 0.5 mg film coated Tablets IP	10's	10'sX10	10X10X10	418,000
177	317	Carbamazepine 100mg Tabs IP	10's	10'sX10	10x10x200	289,000
178	319	Clonazepam 0.5 mg Tabs IP	10's	10'sX10	10'sX10X100	706,000
179	320	Diazepam 5 mg Tabs IP	10's	10'sX10	10'sX10X100	420,000
180	321	Escitalopram 10 mg Tabs IP	10's	10'sX10	10'sX10X100	100,000
181	322	Escitalopram 20 mg Tabs IP	10's	10'sX10	10'sX10X100	100,000
182	323	FLUNARZINE TABLETS 10MG	10's	10'sX10	10'sX10X100	173,000
183	324	FLUNARZINE TABLETS 5MG	10's	10'sX10	10'sX10X100	208,800
184	325	Fluoxetine hydrochloride 20 mg Caps IP	10's	10'sX10	10'sX10X100	302,000
185	326	Methyl Ergometrine 0.125mg Tabs IP	10's	10'sX10	10'sX10X200	195,000
186	327	PHENYTOIN Tablets IP 100 mg	100's in Bottle	1's x 10	1's x 10 x 10	150,000
187	328	Prochlorperazine 5 mg Tabs IP	10's	10'sX10	10'sX10X100	50,000
188	329	Prednisolone Tablets IP 5 MG	15's	15's x 10	(15's x10x10)x 10	1811000
189	330	Prednisolone 10 mg Tabs IP	10's	10's x10	(10's x10x10)x20	1124000
190	331	THYROXINE SODIUM TABLETS IP 50 µg	10's	10's x10	(10's x10x10)x20	1,350,000
191	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2ML	2 ml X 10	2 ml X 10 X 100	500,000
192	336	Allopurinol 100 mg Tabs IP	10's	10'sX10	10'sX10X200	785,000
193	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML	1mlX 10	1mlX10X50	238,000
194	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML	1's x 10	1's x 10 x 20	250,000

195	344	Ciprofloxacin 0.3% w/V Eye drops	5ml	1's x 10	1's x 10 x 20	267,000
196	345	Gentamycin 0.3% W/V Eye drops IP	5 ml	1's X 25	(1's X 25)x 10	300,000
197	351	Xylometazoline 0.1 % w/v Nasal Drop IP	10 ml	10 ml x 10	10 ml x 10 x 20	136,000
198	356	LIGNOCAINE INJECTION IP 2% w/v	30 ML VIAL	1's x 10	1's x 10 x 10	20,000
199	357	Ligncaine 10mg + Adrenaline 0.005mg/ml inj.	30 ml vial	1's x 10	1's x 10 x 10	50,000
200	358	Propofol 10mg/ ml Inj	10ml vial	1's x 10	1's x 10 x 20	30,000
201	360	MIFEPRISTONE Tablets IP 200 mg	1's	1's X10	1's X10 X10	100,000
202	361	OXYTOCIN INJECTION IP 5 iu /ml	1 ML	1's x 10	1's x 10 x 20	821,000
203	364	GLIMEPIRIDE 2 mg + METFORMIN HYDROCHLORIDE 500 mg SR Tablets	15's	15'sx10	15'sx10x100	2,000,000
204	365	GLICLAZIDE 80 mg + METFORMIN HYDROCHLORIDE Tablets 500 mg	10's	10'sX10	10'sx10x100	1,363,000
205	367	VOGLIBOSE Tablets IP 0.3 mg	10's	10'sX10	10'sX10X200	1,500,000
206	368	GLICLAZIDE TABS/CAPS SR 60 MG	10's	10'sX10	10'sX10X200	500,000
207	369	ACARBOSE TABLETS IP 50 MG	10's	10'sx10	10'sX10X200	500,000
208	371	VOGLIBOSE Tablets IP 0.2 mg	10's	10'sx10	10'sX10X200	1,672,000
209	372	METFORMIN HYDROCHLORIDE TABLETS IP PROLONG RELEASE 500 MG	10's	10'sx10	10'sx10x100	2,582,000
210	373	ARTESUNATE INJECTION 60 MG	1 Vial	1 Vial X 10	1 Vialx10x50	160,000
211	374	ARTEMETHER 80 MG + LUMEFANTRINE (BANFLUMETOL) 480 MG SR TABLETS	6's	6's X 10	6's X 10X 100	100,000
212	375	QUININE SULPHATE TABLETS IP 300 MG FILM COATED TABLETS	10's	10'sX10	10'sx10x100	100,000
213	376	IMIPENEM AND CILASTATIN INJ IP	Vial &	1's x 10	1's x 10X20	20,000



		(500mg+500mg)	WFI			
214	377	CLINDAMYCIN CAPSULES IP 300 MG	10's	10's x10	(10's x 10x 10)x10	100,000
215	380	CLARITHROMYCIN Tablets IP 500 mg	4's	4's x 10	4's x 10 x 100	100,000
216	381	CEFIXIME 200 mg + OFLOXACIN 200 mg Tablets	10's	10'sX10	(10's x 10x 10)x10	273,000
217	382	LINEZOLID TABLETS IP 600 MG	10's	10'sX10	(10's x 10x 10)x10	216,000
218	383	CEFPODOXIME 200 mg+ CLAVULANIC ACID 125 mg Tablets	6's	6's X 10	6's X 10X 100	218,000
219	384	ITRACONAZOLE Capsules 100 mg	4's	4's x 10	4's x 10 x 100	427,000
220	385	CEFIXIME 200 mg + CLAVULANIC ACID 125 mg (AS POT.CLAVULANATE )Tablets	10's	10'sX10	10'sX10x200	200,000
221	386	DIETHYLCARBAMAZINE Tablets IP 50 mg	30's	30's x 10	(30's x10)x100	100,000
222	387	TERBINAFINE 250 MG TABLETS	7's	7'sx10	(7'sx10x10) x20	389,000
223	390	ETHAMBUTOL TABLETS IP 800 MG	10's	10'sX10	(10's x 10x 10)x10	50,000
224	391	MOXIFLOXACIN TABLETS 400 MG	5's	5's X 10	5's X 10 X 10	100,000
225	393	ACYCLOVIR DISPERSIBLE TABLETS IP 800 MG	5's	5's X 10	5's X 10 X 10	108,000
226	395	CEFUROXIME 500 mg+ CLAVULANIC ACID 125 mg (AS POT.CLAVULANATE ) Tablets	6's	6's X 10	6's X 10X 100	180,000
227	400	KETOCONAZOLE Tablets IP 200 mg	10's	10'sX10	10's x 10x 200	336,000
228	401	AMOXYCILLIN 250mg WITH POTASSIUM CLAVULANATE 125mg Tablets IP	6's	6's X 10	6's X 10X 100	348,000
229	402	AMOXYCILLIN and POTASSIUM CLAVULANATE Tablets IP (875mg+125mg)	6's	6's X 10	6's X 10X 10	418,000

230	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML	2mlx10	(2X10)X10x15	50,000
231	404	LINEZOLID INFUSION 600 MG/300 ML	300 ML	1's x 10	1's x 10 x 5	50,000
232	405	OFLOXACIN INFUSION IP 200 mg /100 ml	100 ml	100 ml X 6	100 ml X 6 X20	100,000
233	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL	1's x 10	1's x 10X20	50,000
234	407	IVERMECTIN TABLETS 12 MG	10's	10'sX10	10's x 10x 200	42,000
235	414	TRANEXAMIC ACID 500 mg+ MEFENAMIC ACID 250 mg Tablets	10's	10'sX10	(10's x 10x 10)x10	211,000
236	416	PRAZOSIN TABLETS IP 5 MG	15's	15x10	15x10x200	300,000
237	417	TELMISARTAN IP 40 mg+ AMLODIPINE 5 mg Tablets	15's	10's x10	(10's x10x10)x10	2,432,000
238	418	ROSUVASTATIN Tablets IP 20 mg	10's	10'sX10	(10's x10x10)x10	1,271,000
239	422	TORASEMIDE Tablets 10 mg	15's	15x10	15x10x100	429,000
240	423	BISOPROLOL TABLETS 5 MG	10's	10'sx10	10'sX10X100	427,000
241	424	CARVEDILOL TABLETS IP 3.125 MG	10's	10'sx10	10'sX10X100	283,000
242	425	DILTIAZEM TABLETS SR 90 MG	10's	10'sx10	10'sX10X100	438,000
243	426	ACENOCOUMAROL TABLETS 2 MG IP	30's	30's x 10	(30's x10)x100	100,000
244	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's	10's x10	(10's x10x10)x10	1,430,000
245	428	DIGOXIN Tablets IP 250 µg [0.25 mg ]	10's	10's x10	10's x 10x 200	517,000
246	429	ATORVASTATIN 10 mg+ FENOFIBRATES 160 mg Tablets	15's	15'sx10	15'sx10x100	631,000
247	430	AMIODARONE Tablets IP 200 mg	10's	10's x10	10'sX10X100	150,000
248	431	RAMIPRIL and HYDROCHLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's	10's x10	10'sx10x100	700,000

249	432	OLMESARTAN Tablets 40 mg	10's	10's x10	10'sX10X100	974,000
250	434	PROPRANOLOL Tablets IP 40 mg	10's	10's x10	10'sX10X100	696,000
251	435	ROSUVASTATIN 10 mg + FENOFIBRATES 160 mg Tablets	10's	10's x10	10'sX10X100	622,000
252	436	TELMISARTAN 40 mg+ CHLORTHALIDONE 12.5 mg Tablets	10's	10'sx10	10'sX10X100	413,000
253	437	NIFEDIPINE PROLONGED RELEASE Tablets IP 20 mg	10's	10'sx10	10'sX10X200	200,000
254	438	INDAPAMIDE TABLETS IP 1.5 MG	10's	10'sx10	10'sX10X200	123,000
255	439	OLMESARTAN MEDOXOMIL 40 mg + HYDROCHLORTHIAZIDE 12.5 mg Tablets	10's	10'sx10	10'sX10X100	588,000
256	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's	7x10	(7'sx10x10)x1 0	873,000
257	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's	10'sx10	(10'sx10x10)x 10	884,000
258	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's	50'sx10	50'sx10x200	500,000
259	445	OLMESARTAN 20 mg+ AMLODIPINE 5 mg Tablets	10's	10'sx10	(10'sx10x10)x 10	500,000
260	449	SPIRONOLACTONE TABLETS IP 25 MG	15's	15'sx10	15'sx10x100	200,000
261	450	LABETALOL TABLETS IP 100 MG	10's	10'sx10	(10'sx10x10)x 10	86,000
262	451	STREPTOKINASE INJECTION IP 1500000 IU	10 ml & wfi	1'sX10	1'sX10x10	10,000
263	452	WARFARIN TABLETS IP 5 MG	10's	10'sx10	(10'sx10x10)x 20	200,000
264	454	VALSARTAN TABLETS IP 80 MG IP	10's	10'sx10	10'sx10x100	300,000
265	456	ATORVASTATIN Tablets IP 40 mg	10's	10'sx10	(10'sx10x10)x 10	1,904,000
266	457	TORASEMIDE TABLETS 20 MG	10's	10'sx10	(10'sx10x10)x 10	299,000

267	458	LABETALOL INJECTION IP 5 mg/ml	4 ml Vial	1'sx10	1'sx10x50	20,000
268	459	HYDROQUINONE 2 % + MOMETASONE 0.1% + TRETINOIN 0.025 % cream	20gm	20GM X 20	20GM X 20 X20	228,000
269	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	1'sx20	1'sx20x10	291,000
270	463	MUPIROCIN OINTMENT IP 2 % w/w	5gm	1'sx20	1'sx20x10	300,000
271	465	DOMPERIDONE 30 mg+ PANTOPRAZOLE 40 mg Capsules [SR]	10's	10'sx10	(10'sx10x10)x 10	3,901,000
272	466	URSODEOXYCHOLIC ACID Tablets IP 300 mg	10's	10'sx10	(10'sx10x10)x 10	700,000
273	467	DICYCLOMINE 10 mg+ MEFENAMIC ACID 250 mg Tablets	10's	10'sx10	(10'sx10x10)x 10	200,000
274	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML	1'sX10	1'sX10x5	63,000
275	471	OXETACAIN 10 MG+ ALUMINIUM 0.291 MG + MAGNESIUM 98 MG /5 ML Suspension	200 ML	1'sX10	1'sx10x5	121,000
276	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's	10'sx10	(10'sx10x10)x 10	400,000
277	474	DOXYLAMINE SUCCINATE 10 mg+ PYRIDOXINE HCl 10 mg Tablets	30's	30's x 10	(30's x10)x100	360,000
278	475	SUCRALFATE SUSPENSION 500 mg/5ml	200 ml	1'sX10	1'sx10x5	159,000
279	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML EMULSION	170 ML	1'sX10	1'sx10x5	100,000
280	477	CLIDINIUM BROMIDE 2.5 MG+ CHLORDIAZEPOXIDE 5 MG FILM COATED TABLETS	10's	10'sx10	(10'sx10x10)x 200	218,000
281	478	SODIUM PICOSULPHATE 10 mg Tablets	10's	10'sx10	(10'sx10x10)x 200	100,000

282	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 GM SYRUP/10 ML	200 ML	1'sX10	1'sx10x5	100,000
283	482	LEVOSULPIRIDE (SR) 75 mg+ RABEPRAZOLE (EC)20 mg Capsules	10's	10'sx10	10'sx10x100	500,000
284	483	LOPERAMIDE Capsules IP 2 mg	10's	10'sx10	(10'sx10x10)x 200	247,000
285	484	ESOMEPRAZOLE Tablets IP 40 mg (ENTERIC COATED)	10's	10'sx10	(10'sx10x10)x 200	747,000
286	485	PROMETHAZINE (FILM COATED) Tablets IP 25 mg	10's	10'sx10	(10'sx10x10)x 200	100,000
287	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML	1'sx10	1'sx10x50	100,000
288	491	ITOPRIDE Tablets 50 mg	10's	10'sx10	(10'sx10x10)x 200	156,000
289	492	Sulfasalazine Tablets EC BP 500 MG	10's	10's x10	(10's x10x10)x10	101000
290	495	FERROUS AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP	200 ML	1'sX10	1'sx10x5	100,000
291	497	KIT OF MIFEPRISTONE 200 mg (1 TABLET) + MISOPROSTOL 200 mg (4 Tablets )	1's	1's X10	1's X10 X10	50,000
292	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's	10'sx10	(10'sx10x10)x 200	1,603,000
293	499	NORETHISTERONE Tablets IP 5 mg	10's	10'sx10	(10'sx10x10)x 200	170,000
294	500	LEVO-THYROXINE SODIUM TABLETS IP 100 MCG	100's in A Bottle	1'sX 10	(1'sX 10)X200	200,000
295	501	BETAMETHASONE TABLETS IP 0.5 MG	20's	20s X 5	20s X 5 X 100	277,000
296	502	DEFLAZACORT Tablets 6 mg	6's	6'sX10	6'sX10X10	850,000
297	503	METHYLPREDNISOLONE SODIUM SUCCINATE INJECTION 1000 MG PER VIAL	VIAL & WFI	1's x 10	1's x 10X20	50,000

298	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	1 ML	1'sX10	1'sx10x50	79,000
299	506	LEVO-THYROXINE TABLETS IP 50 MCG IP	100's in Bottle	1'sX 10	(1'sX 10)X200	240,000
300	507	CARBIMAZOLE TABLETS IP 5 MG	10's	10'sx10	(10'sx10x10) x 20	1,000,000
301	508	LEVETIRACETAM Tablets 500 mg	10's	10'sx10	10'sx10x10	808,000
302	509	HYDROXYCHLOROQUINE Tablets IP 200 mg	10's	10'sx10	10'sx10x10	552,000
303	510	PARACETAMOL 325 mg+ TRAMADOL 37.5 mg Tablets	10's	10'sx10	10'sx10x10	412,000
304	511	PARACETAMOL Tablets IP 650 mg	15's	15'sx10	15'sx10x50	1,710,000
305	512	ACECLOFENAC 100 mg + PARACETAMOL 325 mg + SERRATIOPEPTIDASE 15 mg Tablets	10's	10'sx10	10'sX10X100	700,000
306	513	PIROXICAM Capsules IP 20 mg	10's	10'sx10	10'sX10X100	92,000
307	514	CHYMOTRYPSIN + TRYPSIN (1:6 ) TABLETS 100K AU	20's	20's X 10	20's X 10 X 100	225,000
308	515	MEFENAMIC ACID SUSPENSION 100 mg/5 ml	60 ml	60ml X 10	60ml X 10 X10	50,000
309	516	ACECLOFENAC Tablets SR/CR 200 mg	10's	10'sx10	10'sX10X200	3,310,000
310	517	THIOLCHOLCHOSIDE 4 mg+ ACECLOFENAC 100 mg Tablets	10's	10'sx10	10'sX10X200	500,000
311	518	BACLOFEN Tablets IP 10 mg	10's	10'sx10	10'sX10X200	356,000
312	519	KETOROLAC TABLETS DT 10 MG	10's	10'sx10	(10'sx10x10) x 20	100,000
313	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's	10'sx10	10'sX10X100	50,000
314	521	TRAMADOL TABLETS SR 100 MG	10's	10'sx10	10'sX10X200	50,000
315	522	ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG	10's	10'sx10	10'sX10X200	300,000

316	525	DICLOFENAC 1.16 w/w+ LINCEED OIL3% w/w+ METHYL SALICYLATE 10% w/w+MENTHOL 5% w/w GEL	30 GM	1'sx20	1'sx20x10	500,000
317	528	PARACETAMOL 500 mg+ PHENYLEPHRINE 10 mg+ CHLORPHENIRAMINE 2 mg Tablets	10's	10'sx10	10'sX10X100	826,000
318	531	GUAIFENESIN 100 mg+ TERBUTALINE 2.5 mg+ BROMHEXINE 8 mg /10 ml SYRUP	100 ml	100 ml X 6	100 ml X 6 X20	200,000
319	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML	100 ml X 6	100 ml X 6 X20	200,000
320	539	ACETYLCYSTEINE Tablets 600 mg	10's	10'sx10	10'sX10X100	150,000
321	541	ACEBROPHYLLINE Capsules 100 mg	10's	10'sx10	10'sX10X200	452,000
322	542	SODIUM CHLORIDE 0.65% w/v NASAL DROPS	20 ml	1'sX10	1'sx10x50	177,000
323	544	FLUTICASONE PROPIONATE RESPULE 0.5 MG/2ML	2 ML	2mlx10	(2X10)X10x15	50,000
324	555	DOXOFYLLINE TABLETS IP 400 MG	10's	10'sx10	10'sX10X100	50,000
325	556	MONTELUKAST 10 MG + FEXOFENADINE HCI 120 MG TABLETS	10's	10'sx10	10'sX10X200	542,000
326	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MDI	1'sx20	1'sx20x10	100,000
327	562	LORATIDINE Tablets BP 10 mg	10's	10'sx10	10'sX10X200	191,000
328	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML	10 ml x 10	10 ml x 10 x 20	100,000
329	569	SILDENAFIL Tablets IP 50 mg	4's	4's x 10	4's x 10 x 100	500,000
330	570	TADALAFIL Tablets 20 mg	4's	4's x 10	4's x 10 x 100	500,000
331	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's	15'sx10	(15'sx10) x 20	500,000
332	574	VACCINE RABIES INJECTION 2.5 IU	1 ml	1'sX10	1'sx10x50	120,000

333	580	ginseng extract 42.5 mg, vitamin A 2500 IU, vitamin B1 1 mg, vitamin B2 1.5 mg, vitamin B6 1 mg, vitamin B12 1 mcg, vitamin C 50 mg, vitamin E 5 mg, vitamin D 200 IU, nicotinamide 10 mg, carbohydrates 0.1 g, folic acid 0.15 mg, ferrous fumarate 30 mg, copper 0.5 mg, potassium sulphate 2 mg, manganese 0.5 mg, magnesium sulphate 3 mg, zinc oxide 10 mg, calcium 75 mg, phosphate 58 mg, iodine 0.1 mg, protein 0.2 g, fat 0.38 g	10's	10'sx10	10'sX10X200	4,320,000
334	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG Tablets	10's	10'sx10	(10'sx10x10) x 20	2,323,000
335	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML	1'sX10	1'sx10x10	1,000,000
336	583	CYPROHEPTADINE Tablets IP 4 mg	10's	10'sx10	10'sX10X200	100,000
337	585	VITAMIN D - CHOLECALCIFEROL 60000 IU /1 GM Sachet	1 Sachet	1'sx10	1'sx10x100	400,000
338	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS )SYRUP	300 ML	1'sX10	1'sx10x5	208,000
339	589	CALCIUM 500 mg+ CALCITRIOL 0.25 mg Tablets	15's	15'sx10	(15'sx10) x 20	441,000
340	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML	1'sX10	1'sx10x50	500,000
341	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6 ) SYRUP	200 ML	1'sX10	1'sx10x5	200,000
342	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML	1'sX10	1'sx10x50	97,000
343	597	VITAMIN B6 TABLETS IP 50 MG	10's	10'sx10	10'sX10X200	200,000
344	598	PREGABALIN 75 mg+ METHYLCOBALAMIN 750 MCG Tablets	10's	10'sx10	10'X 10X 100	700,000
345	599	PREGABALIN TABLETS 75 MG	10's	10'sx10	10'sX10X200	700,000



346	601	Disulfiram IP 500 mg	4s	4'S X 10	4's x 10 x 250	200,000
347	604	Levocetirizine HCL 5mg, Phenylephrine HCL 5mg, Ambroxol HCL 30mg, Paracetamol 325mg	10's	10'sx10	10'X 10X 100	2,880
348	608	Betamethasone 0.05% w/w + Salicylic acid 3% w/w	20 Gm	20GM X 20	20GM X 20 X20	225,000
349	610	Cold Suspn.N/F (Paracetamol 125 mg+ Phenylephrine Hydrochloride IP 5mg +	60ml	60ml X 10	60ml X 10 X10	200,000
350	611	Cyproheptadine, Hydrochloride(anhydrous) IP..2 mg.In a flavoured syrup base ....q.s.	200 ml.	1'sX10	1'sx10x5	100,000
351	612	Dusting Powder (Povidone 5% Powder	10 Gm Container	10gm X 20	10gm X 20X 20	172,000
352	613	Diclofenac Potassium BP 50 mg + Paracetamol 325 mg + Serratiopeptidase 10 mg	10's	10'sx10	10'X 10X 100	477,000
353	614	Ear Drops (Paradichlorobenzene 2%+Benzocaine 2.7%+Chlorbutol 5%+Turpentine Oil15%	10ml	10ml X 10	10ml X 10 X20	133,000
354	621	Iron & Zinc (Carbonyl Iron 50 mg+ Zinc Sulphate Monohydrate USP 61.8 mg equivalent to Elemental Zinc 22.5 mg + Folic Acid IP 0.5mg	15's	15'SX 10	15'SX 10X100	829,000
355	626	Dandruf Shampoo KETOCONAZOLE IP SHAMPOO 2% W/V	100ml Bottle	100 ML X6	100 MLX6X20	157,000
356	630	laxative Suspension Liquid Paraffin 3.75ml+Milk of Magnesia 11.25ml)	170ml Bottle	1'sX10	1'sx10x5	156,000
357	633	Anti-acne Gel Adapalene BP...0.1 % w/w, Clindamycin Phosphate USP equivalent to Clindamycin...1% w/w, Methyl Paraben IP...0.1 % w/w, Phenoxyethanol BP...0.25 % w/w	15 gms.Tube	15gm X 20	15gm X 20 X20	159,000
358	637	Aceclofenac 100 mg + Paracetamol 325 mg +	10's	10'sx10	10'sX 10X 100	859,000

		Chorroxazone 250 mg film coated tab.				
359	639	Mucodilator Expectorant Terbutaline Sulphate 1.25 mg, Bromhexine 4 mg, Guaiphenesin 50 mg, Menthol 2.5 mg per 5 ml	100 ml	100ML X 6	100ML X 6 X20	200,000
360	640	Nimesulide 1% W/W Gel	20 Gm tube	20gm X 20	20gm X 20 X20	137,000
361	643	Paracetamol 125mg+ CPM 1 mg + Sodium Citrate 60mg in a flavour syrup base	60 ml Bottle	60ml X 10	60ml X 10 X10	300,000
362	644	Phenylephrine Hydrochloride 5.00mg Chlorpheniranmine Maleate 2.00mg Drops	15ml Bottle	15ml X 20	15ml X 20 X20	50,000
363	646	Diclofenac diethylamine BP 1.116% (equivalent to diclofenac sodium 1.0%, Linseed oil BP 3.0% + Methyl Salicylate IP 10.0%, Capsiacin USP 0.025%, Menthol IP 0.025%, Benzyl alcohol IP 1.0% (as preservative) In a gel base q.s.	30 Gm	30gmX 20	30gmX 20X20	500,000
364	648	Diclofenac Diethylamine BP 1.16 %, Linseed Oil BP 3 % w/w, Methyl Salicylate IP 10 % w/w, Menthol IP 5 % w/w, Excipients and Propellant q.s. to 100 % w/w Spray	35 gms.	1x10	35gmX10)x25	500,000
365	649	Dicyclomine 10mg + Act. Dimethicone 40mg per ml	10ml Bottle	10ml X 10	10ml X 10 X 20	100,000
366	651	Paracetamol IP...125 mg., Mefanamic Acid IP...50 mg., in a flavoured syrupy base...q.s.	60 ml.	60ml X 10	60ml X 10 X10	73,000
367	653	Syrup Vitamin D3 200 IU + Vitamin B12 2.5 mcg + Calcium Phosphate eq. to elemental Calcium 82 mg / 5 ml	225 ml	1'sX10	1'sx10x5	195,000
368	655	Enzyme Syrup Mix Fruit Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml	1'sX10	1'sx10x5	50,000
369	656	Enzyme Drops Pepsin (1:3000) 5 mg + Fungal Diastase (1:1200)	15ML	15 ml x	15 ml x 20 X	76,000

		33.33 mg/ml		20	20	
370	658	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v	100 ml	100ML X 6	100ML X 6 X20	113,000
371	659	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v	200 ml	1'sX10	1'sx10x5	100,000
372	664	Mouth Ulcer Gel (Choline Salicylate sodium 9% w/v, Benzalkonium Chloride 0.01% w/w)	10 gm	10gm X 20	10gm X 20X 20	217,000
373	666	Pheniramine Maleate I.P. 22.75mg, Methyl Paraben(as preservative) I.P. 0.135% w/v, Propyl Paraben(as preservative) I.P. 0.015% w/v, Water for injection I.P. q.s.	2ml	2 mlx10	2 mlx10x50	100,000
374	667	Paracetamol I.P. 125 mg:+ Promethazine HCl I.P. 5 mg syrup	15ml	15 ml x 20	15 ml x 20 X 20	125,000
375	669	Syrup - Cefuroxime 125mg(as Cefuroxime Axetil USP)	30ml	30 ml x 20	30 ml x 20 X 20	100,000
376	670	Diacerein 50 mg + Methylsulphonylmethane 250 mg + Glucosamine sulphate 750 mg tab.	10's	10'sx10	10'sX 10X 100	337,000
377	671	Diacerein 50 mg + Glucosamine Sulphate 500 mg Tablets	10's	10'sx10	10'sX 10X 100	253,000
378	672	Mometasone Furoate 0.1 % w/w cream	15gm	15gm X 20	15gm X 20 X20	134,000
379	676	Trimcelone Acetonide 0.1 % Mouth Ulcer gel	10gm	10gm X 20	10gm X 20X 20	50,000
380	680	Finastride 5 mg Tablets	10's	10'sx10	10'sX 10X 100	100,000
381	682	Rabeprazole 20mg + Domperidone 10mg Capsules	10's	10'sx10	10'sX 10X 100	953,000
382	683	Rabeprazole Sodium ip 20mg + Itopiride HCL 150mg Capsules	10's	10'sx10	10'sX 10X 100	900,000
383	685	Pantoprazole 40mg + Itopride 150mg S.R. Capsules.	10's	10'sx10	10'sX 10X 100	167,000

384	686	Magaldrate 400 mg + Simethicone 20 mg/ 5ml oral suspension	170 ml	1'sX10	1'sx10x5	117,000
385	687	Lactulose 10gm/15 ml syrup	200ml	1'sx10	1'sx10x10	360,000
386	688	Nitroglycerine Injection 5mg/ ml	10 ml Vial	10ml X 10	10ml X 10 X 20	50,000
387	689	Clotrimazole 100 mgVaginal Tab	10's	10'sx10	10'sX 10X 100	92,000
388	690	Timolol Maleate 0.5 % Eye Drops	5 ml Vial	5ml X 10	5ml X 10 X 20	136,000
389	692	Olopatadine Eye Drops	10 ml Vial	10ml X 10	10ml X 10 X 20	79,000
390	694	Tobramycin Eye Drops	10 ml Vial	10ml X 10	10ml X 10 X 20	136,000
391	697	Sulfacetamide eye drop 10 %	10 ml	10ml X 10	10ml X 10 X 20	76,000
392	698	Sulfacetamide eye drop 20 %	20 ml	20ml X 20	20ml X 20 X 20	66,000
393	699	Acyclovir Eye Ointment	5gm	5gmx20	5gmx20x20	80,000
394	704	Cephalexin 125mg/5ml dry syrup	30ml	30ml X 10	30ml X 10 X 50	62,000
395	705	Levofloxacin 500 mg INFUSION / IV	100ml	100 ml X 6	100 ml X 6 X20	100,000
396	706	Cefpodoxime proxetil 50 mg DS dry syrup	30ml	30ml X 10	30ml X 10 X 50	50,000
397	708	Piroxicam 20 mg buccal tablets	10's	10'sx10	10'sX 10X 100	300,000
398	709	Piroxicam 20 mg with bezyl alcohol injection	1ml	1 mlx10	1 mlx10x50	100,000
399	710	Piroxicam 40 mg with bezyl alcohol injection	2ml	2 mlx10	2 mlx10x50	100,000
400	712	Paracetamol DS 250 mg/5ml syrup	60ml	60ml X 10	60ml X 10 X10	111,000
401	715	Glycerin ip 98%w/w	50 gm	50gm X 20	50gm X 20X 20	123,000

402	716	Urea IP 1 % + Salicylic Acid IP 1% w/w Zinc Sulphate 0.1 % w/w	10 gm	10 gmX20	10 gm x 20x 20	97,000
403	718	Escitalopram 10mg with Clonazepam 0.5mg	10's	10'sx10	10'sX 10X 100	319,000
404	720	Ringer Lactate 500ml IV fluid plastic container using FFS technology	500ml	1'sX10	1'sx10x5	159,000
405	723	Water for Injection amp polypack	10ml	10ml X 10	10ml X 10 X 20	200,000
406	739	Cefuroxime 125 mg tablet	6's	6'sX10	6'sX10X10	100,000
407	740	Clarithromycin 250 mg tablet	10's	10'sx10	10's x 10 x 10	100,000
408	747	Glimipride 3 mg tablet	10's	10'sx10	10's x 10 x 10	1,100,000
409	748	Glimipride 4 mg tablet	10's	10'sx10	10's x 10 x 10	1,100,000
410	753	Clotrimazole 1% w/w, Beclometasone Dipropionate 0.025% w/w 15 ml lotion	15 ml Lotion in Bottle	15 ml x 10	15 ml x 10 x 30	208,000
411	754	Clotrimazole 1% w/w, Beclometasone Dipropionate 0.025% w/w cream 15 gm tube	15 gm Cream	15 gm x 10	15 gmx 10 x 30	520,000
412	755	Povidone-Iodine 10% medicated paint	50 ML	50 ml x 10	(50 ml x 10) x 10	100,000
413	759	Rosuvastatin Tablet 10 mg	15's	15's x 10	15's x 10 x 10	889,000
414	764	Etizolam Tablet 0.5mg	10's	10'sx10	10's x 10 x 10	300,000
415	767	Metformin 1000mg SR + Glimipride 2mg Tablet	10's	10x10	10x10x50	509000
416	768	Acetazolamide Tablets I.P 250mg	10's	10'sx10	(10'sx10x10)x 10	200,000
417	781	Alprazolam-0.25 mg, Fluoxetine 20 mg Tablets	10's	10'sx10	(10'sx10x10)x 20	16000
418	791	Atenolol 25 mg, Amlodipine 5 mg Tablets	14's	14x10	(14'sx10x10)x 10	1,180,000
419	793	Atenolol Tablets 25 mg	14's	14x10	(14'sx10x10)x 10	376000

420	796	Atorvastatin I.P 10mg, Aspirin I.P (EC) 75mg Capsules	10's	10'sx10	(10'sx10x10)x10	1,553,000
421	804	Betamethasone Inj. I.P 4 mg/ml	1 ML	(1ml x10)	(1mlx10x10)x10	1134000
422	822	Cefazolin Sodium Injection IP 500mg	Vial&WFI	1x10	(1x10)x100	19000
423	838	Cilostazol Tablets IP 50mg	10's	10'sx9	(10'sx10x10)x10	38000
424	840	Citicoline Tablets 500mg	10's	10'sx10	(10'sx10x10)x10	48000
425	860	Dextromethorphan HBr Syrup IP 13.5mg/5ml	50ml	1's x10	(1's x10)x10	63000
426	865	Diacerein Capsules IP 50mg	10's	10'sx10	(10'sx10x10)x20	22000
427	884	Erythromycin Estolate Suspension 125 Mg/5ml	60 ML	60mlx10	(60mlx10)x10	21000
428	889	Febuxostat Tablets 80mg	10'S	10'sx10	(10'sx10x10)x20	200000
429	904	Glimepiride 1mg Metformin SR 500mg Tablets	10's	10'sx10	(10'sx10x10)x20	1748000
430	905	Glimepiride 2mg, Metformin Hydrochloride 1g Tablets	10's	10'sx10	(10'sx10x10)x5	162000
431	909	Human Albumin Solution 20%	100ml vial	1'sx10	(1'sx10)x10	50,000
432	926	Ketoconazole Cream 2%w/w	15gm Tube	1 x 25	(1 x 25) x 20	13000
433	933	Leflunomide Tablets IP 20mg	10's	10'sx10	(10'sx10x10)x20	200,000
434	955	Mefenamic Acid 50mg, Paracetamol 125mg/5ml Suspension	60ml	1's x10	(1's x10)x10	196000
435	960	Metformin SR Tablets IP 850mg	10's	10'sx10	(10'sx10x10)x20	309,000
436	978	Nepafenac 0.1% w/v Eye Drop	5ml	1 x 25	(1x25)x20	27000
437	992	Olmesartan FC Tablets 20mg	10's	10'sx10	(10'sx10x10)x20	972,000

438	1005	Phenobarbitone Tablets I.P 30mg	30's	30's x 10	(30's x10)x100	500,000
439	1011	Piracetam Syrup 500mg/5ml	100 ML	1x10	(1x10)x5	14000
440	1012	Piracetam Tablets 400mg	10's	10x10	10x10x100	41000
441	1031	Quetiapine Fumarate Tablets I.P 200mg	10's	10'sx10	(10'sx10x10)x 20	100,000
442	1032	Quetiapine Tablets I.P 100mg	10's	10'sx10	(10'sx10x10)x 20	100,000
443	1044	Rosuvastatin Calcium Tablet I.P 5mg	10's	10'sx10	(10'sx10x10)x 20	1,200,000
444	1049	Sertraline Tablets 50mg	10's	10'sx10	(10'sx10x10)x 20	50000
445	1051	Sertraline Tablets I.P 25mg	10's	10'sx10	(10'sx10x10)x 20	59000
446	1060	Sodium Valproate Tablets 300mg	10's	10'sx10	(10'sx10x10)x 10	144,000
447	1062	Sofosbuvir Tablets 400mg	10's	10'sx10	(10'sx10x10)x 10	100,000
448	1099	Voglibose 0.3 mg, Metformin 500mg Tablets	10's	10'sx10	(10'sx10x10)x 10	684,000
449	1108	Sildenafil Tablets 100 mg	4's	4'sx 10	100 X 10X4's	90000
450	1112	Cinnarizine Tablets 25mg	10's	10x10	100 X 10X10's	299000
451	1127	Human Albumin Solution 20%	50 ml vial	1's x 10	(1's x 10) x 10	50,000
452	1133	LEVO-THYROXINE TABLETS IP 25 MCG	100's in A Bottle	1's x 10	(1'sx10x10)	150,000
453	1134	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	100 ML	1'Sx10	1'Sx10x10	500,000

## **ANNEXURE –X**( Ref:-Clause 7.1)

### **MODEL BANK GUARANTEE FORMAT FOR FURNISHING EMD**

Whereas ..... (hereinafter called the “tenderer”) has submitted their offer dated..... for the supply

Of Drugs (hereinafter called the “tender”) against the purchaser’s tender enquiry No. BBPI/DRUG-050/2017 KNOW ALL MEN by these presents that WE ..... of ..... having our registered office at ..... are bound unto Bureau of Pharma Public Sector Undertakings of India Gurgaon/Delhi(hereinafter called the “Purchaser) in the sum of Rs. One lakh only for which payment will and truly to be made to the said Purchaser, the Bank binds itself, its successors and assigns by these presents. Sealed with the Common Seal of the said Bank this..... day of .....201..

#### **THE CONDITIONS OF THIS OBLIGATION ARE:**

(1) If the tenderer withdraws or amends, impairs or derogates from the tender in any respect within the period of validity of this tender.

(2) If the tenderer having been notified of the acceptance of his tender by the Purchaser during the period of its validity:-

a) If the tenderer fails to furnish the Performance Security for the due performance of the contract.

b) Fails or refuses to accept/execute the contract.

WE undertake to pay the Purchaser up to the above amount upon receipt of its first written demand, without the Purchaser having to substantiate its demand, provided that in its demand the Purchaser will note that the amount claimed by it is due to it owing to the occurrence of one or both the two conditions, specifying the occurred condition or conditions.

This guarantee will remain in force up to 31.03.2018 and any demand in respect thereof should reach the Bank not later than the above date.

.....

(Signature of the authorized officer of the Bank)

.....

Name and designation of the officer

.....

Seal, name & address of the Bank and address of the Branch



## Annexure – XI

{Ref:- clause 8.1(ii)}

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Shelf Life in months	Manufacturing Capacity per year in Units	Manufacturing Batch Size in Units
1	1	Aceclofenac + Paracetamol (100 mg + 325 mg) Tablets	10's			
2	2	Aceclofenac 100 mg Tablets IP	10's			
3	4	Acetaminophen + Tramadol Hydrochloride (325 mg + 37.5 mg) film coated Tablets	10's			
4	5	ASPIRIN Tablets IP 150 mg	14's			
5	6	DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ CHLORZOXAZONE 500 mg Tablets	10's			
6	7	Diclofenac Gel( Diclofenec Diethylamine 1.16 % w/w) BP	15 g			
7	8	Diclofenac Sodium + Serratiopeptidase (50mg + 10mg) Tab	10's			
8	10	Diclofenac Sodium 25mg per ml Inj. IP	3 ml			
9	11	Diclofenac Sodium 50 mg Tab IP	10's			
10	12	Etoricoxib 120mg Tab IP	10's			
11	13	Etoricoxib 90mg Tab IP	10's			
12	14	Ibuprofen 400mg + Paracetamol 325mg Tablets	15's			
13	16	Ibuprofen Tablets IP 400mg	15's			
14	20	Nimesulide 100 mg Tab IP	10's			
15	21	Paracetamol + Diclofenac Sodium (325 mg + 50 mg) Tab	10's			
16	22	Paracetamol 125 mg	60 ml			

		/ 5 ml Syrup IP	bottles			
17	23	Paracetamol 500mg Tab IP	10's			
18	25	Serratiopeptidase Tablets 10 mg	10's			
19	26	Tramadol Hydrochloride 50mg/ml Inj.	2ml			
20	27	Tramadol Hydrochloride 50mg/ml Inj.	1ml			
21	28	Tramadol Hydrochloride 50 mg Tab	10's			
22	30	Amikacin Sulphate 50mg/ml inj. IP	2ml Vial			
23	31	Amikacin 250mg/2ml inj. IP	2ml Vial			
24	32	Amikacin 250mg/ml inj. IP	2ml Vial			
25	35	Amoxycillin + Clavulanic acid (1000 mg + 200mg) Powder for Injection IP	Vial with 10 ml WFI			
26	36	Amoxycillin + Clavulanic acid (200 mg+28.5 mg /5ml) Powder for suspension IP	30 ml bottles			
27	37	Amoxycillin + Clavulanic acid (250 mg + 50 mg) Powder for injection IP	Vial with 10 ml WFI			
28	40	AMOXYCILLIN 250 mg+ CLOXACILLIN 250 mg Capsules	10's			
29	42	Amoxycillin 125 mg Kid Tabs IP	10's			
30	46	Ampicillin Injections I.P. 500mg	Vial & WFI			
31	53	Cefixime Oral Suspension IP 50 mg/5 ml	30 ml bottle			
32	54	Cefixime 100mg film coated Tablets IP	10's			
33	55	Cefixime 200mg film coated Tablets IP	10's			
34	56	Cefoperazone + Sulbactam ( 1g + 1g) Inj. IP	Vial & wfi			

35	57	Cefoperazone + Sulbactam (500 mg + 500 mg) Inj.	Vial & wfi			
36	58	Cefoperazone 1 gm Inj. IP	Vial			
37	59	Cefotaxime Sodium & Sulbactam Sodium (1g + 500 mg) Inj.	Vial & wfi			
38	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	VIAL & WFI			
39	62	Cefotaxime Sodium Injections IP 1000mg	Vial & wfi			
40	63	Cefotaxime Sodium Injections IP 250mg	Vial & wfi			
41	64	Cefotaxime Sodium Injections IP 500mg	2ml Vial & wfi			
42	65	Cefpodoxime 100 mg DT IP	10's			
43	70	Ceftriaxone + Sulbactam (1000 mg + 500 mg) Inj.	Vial & wfi			
44	71	Ceftriaxone + Tazobactam 1000 mg + 125 mg Inj.	Vial & wfi			
45	73	Ceftriaxone +Sulbactam (250 mg + 125 mg) injection	Vial & wfi			
46	75	Ceftriaxone Injections IP 1 g	5ml Vial & WFI			
47	76	Ceftriaxone 250 mg Inj. IP	Vial & wfi			
48	78	Cefuroxime Axetil 250 mg film coated Tablets IP	10's			
49	79	Cefuroxime Axetil 500mg film coated Tablets IP	10's			
50	80	Cephalexin 125 mg Dispersible Tablet IP	10's			
51	81	Cephalexin 250 mg Caps IP	10's			
52	82	Cephalexin 500 mg Caps IP	10's			
53	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG FILM COATED TABLETS	10's			
54	84	Ciprofloxacin +	10's			

		Tinidazole (500 mg + 600 mg) film coated Tablets				
55	87	Clotrimazole 1% w/w ointment IP	15 g tubes			
56	95	Levofloxacin 250 mg film coated Tablets IP	10's			
57	96	Levofloxacin 500 mg film coated Tablets IP	10's			
58	97	Meropenem 1gm Inj. IP	Vial & wfi			
59	98	NORFLOXACIN 400 mg + TINIDAZOLE 600 mg FILM COATED Tablets	10's			
60	100	Ofloxacin + Ornidazole (200 mg + 500 mg) film coated Tablets	10's			
61	101	Ofloxacin 200 mg film coated Tablets IP	10's			
62	102	Ofloxacin 400 mg film coated Tablets IP	10's			
63	103	Piperacillin + Tazobactam 4 g + 0.5 mg Injections	Vial & wfi			
64	105	Roxithromycin 150 mg film coated Tablets IP	10's			
65	107	Tinidazole 300 mg film coated Tablets	10's			
66	108	Tinidazole 500 mg film coated Tablets IP	10's			
67	109	VANCOMYCIN INTRAVENOUS INFUSION IP 500 mg	Vial & WFI			
68	110	Adapalene 0.1 % w/v Gel	15G Tube			
69	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM			
70	115	Calamine lotion 100 ml	100ml bottle			

71	117	CHLORHEXIDINE MOUTHWASH IP 0.2 % w/v	100 ml			
72	125	Povidone Iodine 5%w/w Ointment USP	15 gm tubes			
73	127	Povidone Iodine 5% Solution 100ml	100ml bottle			
74	128	Povidone Iodine 5 % Solution IP	500 ml bottles			
75	129	Povidone Iodine 7.5% Solution IP	500 ml bottles			
76	130	(Chlorhexidine + Cetramide ) (1.5 % w/v + 3% w/v) Solution	100 ml bottles			
77	133	Glibenclamide 2.5 mg Tabs IP	10's			
78	134	Glibenclamide 5 mg Tabs IP	10's			
79	135	Gliclazide 40 mg Tabs IP	10's			
80	136	Gliclazide 80 mg Tabs IP	10's			
81	137	Glimeperide 1mg Tab IP	10's			
82	138	Glimeperide 2mg Tabs IP	10's			
83	142	INSULIN INJECTION IP 40 IU/ml (Insulin Human Recombinant)	10 ml Vial			
84	144	METFORMIN HYDROCHLORIDE SUSTAIN RELEASE TABLETS IP 1000 MG	10's			
85	145	Metformin Hydrochloride 500mg Tabs IP	10's			
86	153	CISPLATIN INJECTION IP 10 MG	VIAL & WFI			
87	155	Doxorubicin 10 mg Inj. IP	Vial			
88	156	Doxorubicin 50 mg Inj. IP	Vial			
89	159	Gemcitabine 1000 mg Inj. IP	Vial			
90	160	Gemcitabine 200 mg Inj. IP	Vial			
91	165	CIPROFLOXACIN	100 ml			

		INJECTION IP 2MG/ML				
92	170	MANNITOL INJECTION IP 20% w/v	100 ml			
93	172	METRONIDAZOLE INJECTION IP 5 mg / ml	100 ml			
94	177	Albendazole (200 mg/ 5ml) Syrup IP	10 ml bottles			
95	178	ALBENDAZOLE 400 mg + IVERMECTIN 6 mg Tablets	1's			
96	180	Bisacodyl 5mg Tablets IP	10's			
97	181	TRICHOLINE CITRATE 275 mg+ CYPROHEPTADINE HCl 2 mg/5ml SYRUP	200 ml			
98	183	Dicyclomine 10 mg Tabs IP	10's			
99	184	Dicyclomine HCL + Paracetamol (20mg + 325 mg) Tablets	10's			
100	186	Domperidone Tablets IP 10 mg	10's			
101	187	Domperidone 5 mg. / 5 ml Syrup IP	30 ml bottles			
102	188	ANTACID Tablets [DRIED Al(OH) <sub>3</sub> + Mg(OH) <sub>2</sub> + SIMETHICONE (250mg + 250mg + 50mg)	10's			
103	191	FAMOTIDINE TABLETS IP 20 MG	14's			
104	192	FAMOTIDINE TABLETS IP 40 MG	14's			
105	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's			
106	197	Lactulose Syrup 10 gm/ 15 ml	100 ml bottle			
107	198	Aluminium Hydroxide + Magnesium Hydroxide (250+250mg / 5ml) Suspension	170 ml			
108	199	Metoclopramide 10	10's			

		mg Tabs IP				
109	203	Misoprostol 200 mcg film coated Tablets IP	4's			
110	206	Omeprazole + Domperidone (20 mg + 10 mg) Caps	10's			
111	207	Omeprazole 20 mg capsules IP	10's			
112	208	ONDANSETRON INJECTION IP 2 mg/ml	2 ML			
113	209	Ondansetron 4 mg Tabs IP	10's			
114	210	Ornidazole 500 mg film coated Tablets IP	10's			
115	212	Pantoprazole 40 mg enteric coated Tablets IP	10's			
116	213	Pantoprazole 40mg Inj.	vial			
117	214	Rabeprazole + Domperidone SR (20 mg + 30 mg)caps.	10's			
118	215	Rabeprazole 20 mg enteric coated Tablets IP	10's			
119	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML			
120	218	RANITIDINE Tablets IP 300 mg FILM COATED	10's			
121	220	Calcium Carbonate 500mg + Vitamin D3 250 IU Tablets film coated	10's			
122	223	PYRIDOXINE HCl 10 mg+ DOXYLAMINE 10 mg + FOLIC ACID 2.5 mg Tablets	30's			
123	224	Folic Acid 5mg Tablet 10's	15's			
124	225	Iron(eq. to elemental iron 50mg) + Folic Acid(0.5mg) /15ml Syrup	200 ml bottles			
125	227	Polyvitamin (Prophylactic) NFI	10's			

		film coated Tablets				
126	229	Haematinic Syrup of Iron , acid and Vitamin B12 100ml	100ml bottle			
127	230	VITAMIN B COMPLEX (B1,B2,B6,B12) & VIT. C WITH ZINC 22.5 MG CAPSULES	10's			
128	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's			
129	232	VITAMIN B-VOMPLEX Syrup NFI	200 ML			
130	235	BUDESONIDE RESPULES 0.5 MG	2 ML			
131	239	Cetirizine (5 mg/ 5 ml) Syrup IP	60 ml bottles			
132	240	Cetirizine 10mg film coated Tablets IP	10's			
133	243	COUGH SYRUP [DIPHEN.14 mg. + AMMONIUM CHL.135 mg. + SOD.CIT.57 mg. + MENTHOL 0.9 mg/5ml]	110 ml			
134	244	Theophylline 25.3 mg+ Etophylline 84.7mg /2ml Injections	2ml			
135	246	Fexofenadine 120 mg film coated Tablets IP	10's			
136	247	Fexofenadine 180 mg film coated Tablets IP	10's			
137	248	Levocetirizine 5 mg film coated Tablets IP	10's			
138	250	Montelukast Sodium 5 mg Tab IP	10's			
139	251	Montelukast Sodium 10 mg Tab IP	10's			
140	252	Montelukast Sodium + Levocetirizine (10 mg + 5mg) film coated Tablets	10's			
141	253	PHENIRAMINE Tablets IP 25 mg	15's			



142	256	SALBUTAMOL Tablets IP 2 MG	10's			
143	260	Salbutamol Tablets IP 4mg	10's			
144	263	Amlodipine + Atenolol (5 mg + 50 mg) film coated Tablets	10's			
145	264	Amlodipine 5mg Tablets IP	10's			
146	265	Atenolol 50 mg Tabs IP	14's			
147	266	Atorvastatin 10mg film coated Tablets IP	10's			
148	267	Atorvastatin 20 mg film coated Tablets IP	10's			
149	269	Clopidogrel 75mg Tabs IP	10's			
150	270	ASPIRIN 75 mg + CLOPIDOGREL 75 mg Tablets	10's			
151	273	Dobutamine 250 mg/ 20ml Inj. IP	Vial			
152	275	Enalapril Tablets I.P. 5mg	10's			
153	276	Enoxaparin 40 mg/0.4 ml Inj. IP	0.4 ml			
154	277	Enoxaparin 60 mg/0.6 ml Inj. IP	0.6 ml			
155	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML			
156	279	Furosemide 40 mg Tabs IP	10's			
157	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's			
158	286	Lisinopril 5mg Tabs IP	10's			
159	287	Losartan + H.Ch. Thiazide (50 mg + 12.5mg) film coated Tablets IP	10's			
160	288	Losartan 25mg film coated Tablets IP	10's			
161	290	Metoprolol 25 mg Tabs IP	10's			
162	291	Metoprolol 50 mg	10's			

		Tabs IP				
163	293	Ramipril 2.5 mg Tabs IP	10's			
164	294	Ramipril 5 mg Tabs IP	10's			
165	298	Telmisartan + Hydrochlorthiazide (40 mg + 12.5 mg ) Tabs	10's			
166	299	TELMISARTAN Tablets IP 20 mg	10's			
167	300	Telmisartan 40 mg Tabs IP	10's			
168	301	Tranexamic Acid 500 mg Tabs IP	10's			
169	302	TRANEXAMIC ACID 100 MG/ ML injection	5 ML			
170	304	Arteether 150mg/2ml inj IP	2ml Vial			
171	305	Chloroquine Phosphate 250 mg film coated Tablets	10's			
172	306	PRIMAQUINE TABLETS IP 15 MG	10's			
173	311	Disodium hydrogen Citrate (Alkalyser) 1.4 mg/5ml Syrup	100 ml bottles			
174	312	Oral Rehydration Salts Citrate IP 21 GM (WHO Formula) Sachet IP	1S			
175	313	Alprazolam 0.25 mg film coated Tablets IP	10's			
176	314	Alprazolam 0.5 mg film coated Tablets IP	10's			
177	317	Carbamazepine 100mg Tabs IP	10's			
178	319	Clonazepam 0.5 mg Tabs IP	10's			
179	320	Diazepam 5 mg Tabs IP	10's			
180	321	Escitalopram 10 mg Tabs IP	10's			
181	322	Escitalopram 20 mg Tabs IP	10's			
182	323	FLUNARZINE TABLETS 10MG	10's			

183	324	FLUNARZINE TABLETS 5MG	10's			
184	325	Fluoxetine hydrochloride 20 mg Caps IP	10's			
185	326	Methyl Ergometrine 0.125mg Tabs IP	10's			
186	327	PHENYTOIN Tablets IP 100 mg	100's in Bottle			
187	328	Prochlorperazine 5 mg Tabs IP	10's			
188	329	Prednisolone Tablets IP 5 MG	15's			
189	330	Prednisolone 10 mg Tabs IP	10's			
190	331	THYROXINE SODIUM TABLETS IP 50 µg	10's			
191	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2ML			
192	336	Allopurinol 100 mg Tabs IP	10's			
193	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML			
194	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML			
195	344	Ciprofloxacin 0.3% w/V Eye drops	5ml			
196	345	Gentamycin 0.3% W/V Eye drops IP	5 ml			
197	351	Xylometazoline 0.1 % w/v Nasal Drop IP	10 ml			
198	356	LIGNOCAINE INJECTION IP 2% w/v	30 ML VIAL			
199	357	Ligncaine 10mg + Adrenaline 0.005mg/ml inj.	30 ml vial			
200	358	Propofol 10mg/ ml Inj	10ml vial			
201	360	MIFEPRISTONE Tablets IP 200 mg	1's			
202	361	OXYTOCIN INJECTION IP 5 iu /ml	1 ML			
203	364	GLIMEPIRIDE 2 mg + METFORMIN HYDROCHLORIDE 500 mg SR Tablets	15's			
204	365	GLICLAZIDE 80 mg +	10's			

		METFORMIN HYDROCHLORIDE Tablets 500 mg				
205	367	VOGLIBOSE Tablets IP 0.3 mg	10's			
206	368	GLICLAZIDE TABS/CAPS SR 60 MG	10's			
207	369	ACARBOSE TABLETS IP 50 MG	10's			
208	371	VOGLIBOSE Tablets IP 0.2 mg	10's			
209	372	METFORMIN HYDROCHLORIDE TABLETS IP PROLONG RELEASE 500 MG	10's			
210	373	ARTESUNATE INJECTION 60 MG	1 Vial			
211	374	ARTEMETHER 80 MG + LUMEFANTRINE (BANFLUMETOL) 480 MG SR TABLETS	6's			
212	375	QUININE SULPHATE TABLETS IP 300 MG FILM COATED TABLETS	10's			
213	376	IMIPENEM AND CILASTATIN INJ IP (500mg+500mg)	Vial & WFI			
214	377	CLINDAMYCIN CAPSULES IP 300 MG	10's			
215	380	CLARITHROMYCIN Tablets IP 500 mg	4's			
216	381	CEFIXIME 200 mg + OFLOXACIN 200 mg Tablets	10's			
217	382	LINEZOLID TABLETS IP 600 MG	10's			
218	383	CEFPODOXIME 200 mg+ CLAVULANIC ACID 125 mg Tablets	6's			
219	384	ITRACONAZOLE Capsules 100 mg	4's			
220	385	CEFIXIME 200 mg + CLAVULANIC ACID 125 mg (AS POT.CLAVULANATE )Tablets	10's			
221	386	DIETHYLCARBAMAZI NE Tablets IP 50 mg	30's			
222	387	TERBINAFINE 250	7's			

		MG TABLETS				
223	390	ETHAMBUTOL TABLETS IP 800 MG	10's			
224	391	MOXIFLOXACIN TABLETS 400 MG	5's			
225	393	ACYCLOVIR DISPERSIBLE TABLETS IP 800 MG	5's			
226	395	CEFUROXIME 500 mg+ CLAVULANIC ACID 125 mg (AS POT.CLAVULANATE ) Tablets	6's			
227	400	KETOCONAZOLE Tablets IP 200 mg	10's			
228	401	AMOXYCILLIN 250mg WITH POTASSIUM CLAVULANATE 125mg Tablets IP	6's			
229	402	AMOXYCILLIN and POTASSIUM CLAVULANATE Tablets IP (875mg+125mg)	6's			
230	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML			
231	404	LINEZOLID INFUSION 600 MG/300 ML	300 ML			
232	405	OFLOXACIN INFUSION IP 200 mg /100 ml	100 ml			
233	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL			
234	407	IVERMECTIN TABLETS 12 MG	10's			
235	414	TRANEXAMIC ACID 500 mg+ MEFENAMIC ACID 250 mg Tablets	10's			
236	416	PRAZOSIN TABLETS IP 5 MG	15's			
237	417	TELMISARTAN IP 40 mg+ AMLODIPINE 5 mg Tablets	15's			
238	418	ROSUVASTATIN Tablets IP 20 mg	10's			
239	422	TORASEMIDE Tablets 10 mg	15's			

240	423	BISOPROLOL TABLETS 5 MG	10's			
241	424	CARVEDILOL TABLETS IP 3.125 MG	10's			
242	425	DILTIAZEM TABLETS SR 90 MG	10's			
243	426	ACENOCOUMAROL TABLETS 2 MG IP	30's			
244	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's			
245	428	DIGOXIN Tablets IP 250 µg [0.25 mg ]	10's			
246	429	ATORVASTATIN 10 mg+ FENOFIBRATES 160 mg Tablets	15's			
247	430	AMIODARONE Tablets IP 200 mg	10's			
248	431	RAMIPRIL and HYDROCHLORTHIAZID E TABLETS IP (5MG+12.5 MG)	10's			
249	432	OLMESARTAN Tablets 40 mg	10's			
250	434	PROPRANOLOL Tablets IP 40 mg	10's			
251	435	ROSUVASTATIN 10 mg + FENOFIBRATES 160 mg Tablets	10's			
252	436	TELMISARTAN 40 mg+ CHLORTHALIDONE 12.5 mg Tablets	10's			
253	437	NIFEDIPINE PROLONGED RELEASE Tablets IP 20 mg	10's			
254	438	INDAPAMIDE TABLETS IP 1.5 MG	10's			
255	439	OLMESARTAN MEDOXOMIL 40 mg + HYDROCHLORTHIAZID E 12.5 mg Tablets	10's			
256	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's			
257	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's			
258	443	ISOSORBIDE DINITRATE TABLETS	50's			

		IP 5 MG				
259	445	OLMESARTAN 20 mg+ AMLODIPINE 5 mg Tablets	10's			
260	449	SPIRONOLACTONE TABLETS IP 25 MG	15's			
261	450	LABETALOL TABLETS IP 100 MG	10's			
262	451	STREPTOKINASE INJECTION IP 1500000 IU	10 ml & wfi			
263	452	WARFARIN TABLETS IP 5 MG	10's			
264	454	VALSARTAN TABLETS IP 80 MG IP	10's			
265	456	ATORVASTATIN Tablets IP 40 mg	10's			
266	457	TORASEMIDE TABLETS 20 MG	10's			
267	458	LABETALOL INJECTION IP 5 mg/ml	4 ml Vial			
268	459	HYDROQUINONE 2 % + MOMETASONE 0.1% + TRETINOIN 0.025 % cream	20gm			
269	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM			
270	463	MUPIROCIN OINTMENT IP 2 % w/w	5gm			
271	465	DOMPERIDONE 30 mg+ PANTOPRAZOLE 40 mg Capsules [SR]	10's			
272	466	URSODEOXYCHOLIC ACID Tablets IP 300 mg	10's			
273	467	DICYCLOMINE 10 mg+ MEFENAMIC ACID 250 mg Tablets	10's			
274	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML			
275	471	OXETACAINE 10 MG+ ALUMINIUM 0.291 MG + MAGNESIUM 98 MG /5 ML	200 ML			

		Suspension				
276	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's			
277	474	DOXYLAMINE SUCCINATE 10 mg+ PYRIDOXINE HCl 10 mg Tablets	30's			
278	475	SUCRALFATE SUSPENSION 500 mg/5ml	200 ml			
279	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML EMULSION	170 ML			
280	477	CLIDINIUM BROMIDE 2.5 MG+ CHLORDIAZEPOXIDE 5 MG FILM COATED TABLETS	10's			
281	478	SODIUM PICOSULPHATE 10 mg Tablets	10's			
282	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 GM SYRUP/10 ML	200 ML			
283	482	LEVOSULPIRIDE (SR) 75 mg+ RABEPRAZOLE (EC)20 mg Capsules	10's			
284	483	LOPERAMIDE Capsules IP 2 mg	10's			
285	484	ESOMEPRAZOLE Tablets IP 40 mg (ENTERIC COATED)	10's			
286	485	PROMETHAZINE (FILM COATED) Tablets IP 25 mg	10's			
287	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML			
288	491	ITOPRIDE Tablets 50 mg	10's			
289	492	Sulfasalazine Tablets EC BP 500 MG	10's			
290	495	FERROUS	200 ML			



		AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP				
291	497	KIT OF MIFEPRISTONE 200 mg (1 TABLET) + MISOPROSTOL 200 mg (4 Tablets )	1's			
292	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's			
293	499	NORETHISTERONE Tablets IP 5 mg	10's			
294	500	LEVO-THYROXINE SODIUM TABLETS IP 100 MCG	100's in A Bottle			
295	501	BETAMETHASONE TABLETS IP 0.5 MG	20's			
296	502	DEFLAZACORT Tablets 6 mg	6's			
297	503	METHYLPREDNISOLONE SODIUM SUCCINATE INJECTION 1000 MG PER VIAL	VIAL & WFI			
298	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	1 ML			
299	506	LEVO-THYROXINE TABLETS IP 50 MCG IP	100's in Bottle			
300	507	CARBIMAZOLE TABLETS IP 5 MG	10's			
301	508	LEVETIRACETAM Tablets 500 mg	10's			
302	509	HYDROXYCHLOROQUINE Tablets IP 200 mg	10's			
303	510	PARACETAMOL 325 mg+ TRAMADOL 37.5 mg Tablets	10's			
304	511	PARACETAMOL Tablets IP 650 mg	15's			
305	512	ACECLOFENAC 100 mg + PARACETAMOL 325 mg + SERRATIOPEPTIDASE	10's			

		15 mg Tablets				
306	513	PIROXICAM Capsules IP 20 mg	10's			
307	514	CHYMOTRYPSIN + TRYPSIN (1:6 ) TABLETS 100K AU	20's			
308	515	MEFENAMIC ACID SUSPENSION 100 mg/5 ml	60 ml			
309	516	ACECLOFENAC Tablets SR/CR 200 mg	10's			
310	517	THIOLCHOLCHOSIDE 4 mg+ ACECLOFENAC 100 mg Tablets	10's			
311	518	BACLOFEN Tablets IP 10 mg	10's			
312	519	KETOROLAC TABLETS DT 10 MG	10's			
313	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's			
314	521	TRAMADOL TABLETS SR 100 MG	10's			
315	522	ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG	10's			
316	525	DICLOFENAC 1.16 w/w+ LINCEED OIL3% w/w+ METHYL SALICYLATE 10% w/w+MENTHOL 5% w/w GEL	30 GM			
317	528	PARACETAMOL 500 mg+ PHENYLEPHRINE 10 mg+ CHLORPHENIRAMINE 2 mg Tablets	10's			
318	531	GUAIFENESIN 100 mg+ TERBUTALINE 2.5 mg+ BROMHEXINE 8 mg /10 ml SYRUP	100 ml			
319	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML			
320	539	ACETYLCYSTEINE Tablets 600 mg	10's			
321	541	ACEBROPHYLLINE Capsules 100 mg	10's			

322	542	SODIUM CHLORIDE 0.65% w/v NASAL DROPS	20 ml			
323	544	FLUTICASONE PROPIONATE RESPULE 0.5 MG/2ML	2 ML			
324	555	DOXOFYLLINE TABLETS IP 400 MG	10's			
325	556	MONTELUKAST 10 MG + FEXOENADINE HCl 120 MG TABLETS	10's			
326	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MDI			
327	562	LORATIDINE Tablets BP 10 mg	10's			
328	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML			
329	569	SILDENAFIL Tablets IP 50 mg	4's			
330	570	TADALAFIL Tablets 20 mg	4's			
331	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's			
332	574	VACCINE RABIES INJECTION 2.5 IU	1 ml			
333	580	ginseng extract 42.5 mg, vitamin A 2500 IU, vitamin B1 1 mg, vitamin B2 1.5 mg, vitamin B6 1 mg, vitamin B12 1 mcg, vitamin C 50 mg, vitamin E 5 mg, vitamin D 200 IU, nicotinamide 10 mg, carbohydrates 0.1 g, folic acid 0.15 mg, ferrous fumarate 30 mg, copper 0.5 mg, potassium sulphate 2 mg, manganese 0.5 mg, magnesium sulphate 3 mg, zinc oxide 10 mg, calcium 75 mg, phosphate 58 mg, iodine 0.1 mg,	10's			

		protein 0.2 g, fat 0.38 g				
334	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG Tablets	10's			
335	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML			
336	583	CYPROHEPTADINE Tablets IP 4 mg	10's			
337	585	VITAMIN D - CHOLECALCIFEROL 60000 IU /1 GM Sachet	1 Sachet			
338	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS )SYRUP	300 ML			
339	589	CALCIUM 500 mg+ CALCITRIOL 0.25 mg Tablets	15's			
340	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML			
341	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6 ) SYRUP	200 ML			
342	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML			
343	597	VITAMIN B6 TABLETS IP 50 MG	10's			
344	598	PREGABALIN 75 mg+ METHYLCOBALAMIN 750 MCG Tablets	10's			
345	599	PREGABALIN TABLETS 75 MG	10's			
346	601	Disulfiram IP 500 mg	4s			
347	604	Levocetirizine HCL 5mg, Phenylephrine HCL 5mg, Ambroxol HCL 30mg, Paracetamol 325mg	10's			
348	608	Betamethasone 0.05% w/w + Salicylic acid 3% w/w	20 Gm			
349	610	Cold Suspns.N/F	60ml			

		(Paracetamol 125 mg+ Phenylephrine Hydrochloride IP 5mg +				
350	611	Cyproheptadine, Hydrochloride(anhydrous) IP..2 mg.In a flavoured syrup base ....q.s.	200 ml.			
351	612	Dusting Powder (Povidone 5% Powder	10 Gm Container			
352	613	Diclofenac Potassium BP 50 mg + Paracetamol 325 mg + Serratiopeptidase 10 mg	10's			
353	614	Ear Drops (Paradichlorobenzene 2%+Benzocaine 2.7%+Chlorbutol 5%+Turpentine Oil15%	10ml			
354	621	Iron & Zinc (Carbonyl Iron 50 mg+ Zinc Sulphate Monohydrate USP 61.8 mg equivalent to Elemental Zinc 22.5 mg + Folic Acid IP 0.5mg	15's			
355	626	Dandruf Shampoo KETOCONAZOLE IP SHAMPOO 2% W/V	100ml Bottle			
356	630	laxative Suspension Liquid Paraffin 3.75ml+Milk of Magnesia 11.25ml)	170ml Bottle			
357	633	Anti-acne Gel Adapalene BP...0.1 % w/w, Clindamycin Phosphate USP equivalent to Clindamycin...1% w/w, Methyl Paraben IP...0.1 % w/w, Phenoxyethanol BP...0.25 % w/w	15 gms.Tube			
358	637	Aceclofenac 100 mg + Paracetamol 325 mg + Chorzoxazone	10's			

		250 mg film coated tab.				
359	639	Mucodilator Expectorant Terbutaline Sulphate 1.25 mg, Bromhexine 4 mg, Guaiphenesin 50 mg, Menthol 2.5 mg per 5 ml	100 ml			
360	640	Nimesulide 1% W/W Gel	20 Gm tube			
361	643	Paracetamol 125mg+ CPM 1 mg + Sodium Citrate 60mg in a flavour syrup base	60 ml Bottle			
362	644	Phenylephrine Hydrochloride 5.00mg Chlorpheniranmine Maleate 2.00mg Drops	15ml Bottle			
363	646	Diclofenac diethylamine BP 1.116% (equivalent to diclofenac sodium 1.0%, Linseed oil BP 3.0% + Methyl Salicylate IP 10.0%, Capsiacin USP 0.025%, Menthol IP 0.025%, Benzyl alcohol IP 1.0% (as preservative) In a gel base q.s.	30 Gm			
364	648	Diclofenac Diethylamine BP 1.16 %, Linseed Oil BP 3 % w/w, Methyl Salicylate IP 10 % w/w, Menthol IP 5 % w/w, Excipients and Propellant q.s. to 100 % w/w <b>Spray</b>	35 gms.			
365	649	Dicyclomine 10mg + Act. Dimethicone 40mg per ml	10ml Bottle			
366	651	Paracetamol IP...125 mg., Mefanamic Acid IP...50 mg., in a flavoured syrupy base...q.s.	60 ml.			

367	653	Syrup Vitamin D3 200 IU + Vitamin B12 2.5 mcg + Calcium Phosphate eq. to elemental Calcium 82 mg / 5 ml	225 ml			
368	655	Enzyme Syrup Mix Fruit Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml			
369	656	Enzyme Drops Pepsin (1:3000) 5 mg + Fungal Diastase (1:1200) 33.33 mg/ml	15ML			
370	658	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v	100 ml			
371	659	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v	200 ml			
372	664	Mouth Ulcer Gel (Choline Salicylate sodium 9% w/v, Benzalkonium Chloride 0.01% w/w)	10 gm			
373	666	Pheniramine Maleate I.P. 22.75mg, Methyl Paraben(as preservative) I.P. 0.135% w/v, Propyl Paraben(as preservative) I.P. 0.015% w/v, Water for injection I.P. q.s.	2ml			
374	667	Paracetamol I.P. 125 mg:+ Promethazine HCl I.P. 5 mg syrup	15ml			
375	669	Syrup - Cefuroxime 125mg(as Cefuroxime Axetil USP)	30ml			
376	670	Diacerein 50 mg + Methylsulphonylme thane 250 mg + Glucosamine sulphate 750 mg tab.	10's			
377	671	Diacerein 50 mg + Glucosamine Sulphate 500 mg Tablets	10's			

378	672	Mometasone Furoate 0.1 % w/w cream	15gm			
379	676	Trimcelone Acetonide 0.1 % Mouth Ulcer gel	10gm			
380	680	Finastride 5 mg Tablets	10's			
381	682	Rabeprazole 20mg + Domperidone 10mg Capsules	10's			
382	683	Rabeprazole Sodium ip 20mg + Itopiride HCL 150mg Capsules	10's			
383	685	Pantoprazole 40mg + Itopride 150mg S.R. Capsules.	10's			
384	686	Magaldrate 400 mg + Simethiocone 20 mg/ 5ml oral suspension	170 ml			
385	687	Lactulose 10gm/15 ml syrup	200ml			
386	688	Nitroglycerine Injection 5mg/ ml	10 ml Vial			
387	689	Clotrimazole 100 mgVaginal Tab	10's			
388	690	Timolol Maeleate 0.5 % Eye Drops	5 ml Vial			
389	692	Olopattadine Eye Drops	10 ml Vial			
390	694	Tobramycin Eye Drops	10 ml Vial			
391	697	Sulfacetamide eye drop 10 %	10 ml			
392	698	Sulfacetamide eye drop 20 %	20 ml			
393	699	Acyclovir Eye Ointment	5gm			
394	704	Cephalexin 125mg/5ml dry syrup	30ml			
395	705	Levofloxacin 500 mg INFUSION / IV	100ml			
396	706	Cefpodoxime proxetil 50 mg DS dry syrup	30ml			
397	708	Piroxicam 20 mg buccal tablets	10's			
398	709	Piroxicam 20 mg with bezyl alcohol injection	1ml			
399	710	Piroxicam 40 mg with bezyl alcohol	2ml			



		injection				
400	712	Paracetamol DS 250 mg/5ml syrup	60ml			
401	715	Glycerin ip 98%w/w	50 gm			
402	716	Urea IP 1 % + Salicylic Acid IP 1% w/w Zinc Sulphate 0.1 % w/w	10 gm			
403	718	Escitalopram 10mg with Clonazepam 0.5mg	10's			
404	720	Ringer Lactate 500ml IV fluid plastic container using FFS technology	500ml			
405	723	Water for Injection amp polypack	10ml			
406	739	Cefuroxime 125 mg tablet	6's			
407	740	Clarithromycin 250 mg tablet	10's			
408	747	Glimipride 3 mg tablet	10's			
409	748	Glimipride 4 mg tablet	10's			
410	753	Clotrimazole 1% w/w, Beclometasone Dipropionate 0.025% w/w 15 ml lotion	15 ml Lotion in Bottle			
411	754	Clotrimazole 1% w/w, Beclometasone Dipropionate 0.025% w/w cream 15 gm tube	15 gm Cream			
412	755	Povidone-Iodine 10% medicated paint	50 ML			
413	759	Rosuvastatin Tablet 10 mg	15's			
414	764	Etizolam Tablet 0.5mg	10's			
415	767	Metformin 1000mg SR + Glimipride 2mg Tablet	10's			
416	768	Acetazolamide Tablets I.P 250mg	10's			
417	781	Alprazolam-0.25 mg, Fluoxetine 20 mg Tablets	10's			

418	791	Atenolol 25 mg, Amlodipine 5 mg Tablets	14's			
419	793	Atenolol Tablets 25 mg	14's			
420	796	Atorvastatin I.P 10mg, Aspirin I.P (EC) 75mg Capsules	10's			
421	804	Betamethasone Inj. I.P 4 mg/ml	1 ML			
422	822	Cefazolin Sodium Injection IP 500mg	Vial&WFI			
423	838	Cilostazol Tablets IP 50mg	10's			
424	840	Citicoline Tablets 500mg	10's			
425	860	Dextromethorphan HBr Syrup IP 13.5mg/5ml	50ml			
426	865	Diacerein Capsules IP 50mg	10's			
427	884	Erythromycin Estolate Suspension 125 Mg/5ml	60 ML			
428	889	Febuxostat Tablets 80mg	10'S			
429	904	Glimepiride 1mg Metformin SR 500mg Tablets	10's			
430	905	Glimepiride 2mg, Metformin Hydrochloride 1g Tablets	10's			
431	909	Human Albumin Solution 20%	100ml vial			
432	926	Ketoconazole Cream 2%w/w	15gm Tube			
433	933	Leflunomide Tablets IP 20mg	10's			
434	955	Mefenamic Acid 50mg, Paracetamol 125mg/5ml Suspension	60ml			
435	960	Metformin SR Tablets IP 850mg	10's			
436	978	Nepafenac 0.1% w/v Eye Drop	5ml			
437	992	Olmesartan FC Tablets 20mg	10's			
438	1005	Phenobarbitone	30's			

		Tablets I.P 30mg				
439	1011	Piracetam Syrup 500mg/5ml	100 ML			
440	1012	Piracetam Tablets 400mg	10's			
441	1031	Quetiapine Fumarate Tablets I.P 200mg	10's			
442	1032	Quetiapine Tablets I.P 100mg	10's			
443	1044	Rosuvastatin Calcium Tablet I.P 5mg	10's			
444	1049	Sertraline Tablets 50mg	10's			
445	1051	Sertraline Tablets I.P 25mg	10's			
446	1060	Sodium Valproate Tablets 300mg	10's			
447	1062	Sofosbuvir Tablets 400mg	10's			
448	1099	Voglibose 0.3 mg, Metformin 500mg Tablets	10's			
449	1108	Sildenafil Tablets 100 mg	4's			
450	1112	Cinnarizine Tablets 25mg	10's			
451	1127	Human Albumin Solution 20%	50 ml vial			
452	1133	LEVO-THYROXINE TABLETS IP 25 MCG	100's in A Bottle			
453	1134	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	100 ML			

**ANNEXURE -XII**

**Ref. Clause No.10.1**

**Performance Security Bank Guarantee**

(unconditional)

To: Bureau of Pharma Public Sector Undertakings of India, (Name of purchaser) IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

**WHEREAS**.....(Name of the Supplier) herein called “the Supplier” has undertaken, in pursuance of Tender **BPPI/DRUG-050/2017 Dtd. 22/05/2017** to supply of **Drugs for the year 2017-19**, (Description of Goods and Services) hereinafter called “the Contract”.

**AND WHEREAS** it has been stipulated by you in the said Contract that the Supplier shall furnish you with a Bank Guarantee for the sum specified therein as security for compliance with the Supplier’s performance obligations in accordance with the Contract.

**AND WHEREAS** we have agreed to give the Supplier a Guarantee

**THEREFORE WE** hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, upto a total of .....(Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the Contract and without cavil or argument., any sum or sums within the limit of .....(Amount of the Guarantee in Words and Figures) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until the .....day of.....2019.

Guarantors

Signature and Seal of

.....  
.....  
.....

Date.....2016

Address.....

.....

### **ANNEXURE-XIII**

#### **Ref. Clause No.10.2**

**(NOTE:-In case Bid is submitted by the Marketer, the Agreement is be signed by Marketer as well Manufacturer)**

### **AGREEMENT**

THIS AGREEMENT made the .....day of .....2016 Between Bureau of Pharma Public Sector Undertakings of India, IDPL Complex, Old-Delhi Gurgaon Road, Dundahera, Gurgaon 122016 (Haryana)

(Name of purchaser) of (Country of Purchaser) (here in after “the Purchaser”) of the one part and .....(Name of Supplier) of .....(City and Country of Supplier) (herein after called “the Supplier”) of the other part :

WHEREAS the Purchaser is desirous that certain Goods and ancillary services viz; Supply of Drugs in the tender Reference No. BPPI/DRUG-050/2017 (Brief Description of Goods and Services) and has accepted a bid by the Supplier for the supply of those goods and services for the sum of .....(Contract Price in Words and Figures( hereinafter called “the Contract Price”).

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to, and they shall be deemed to form and be read and construed as part of this agreement.
2. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz
  - a. The Letter of Acceptance issued by the purchaser.
  - b. The Notice Inviting Tender
  - c. The supplier’s bid including enclosures, annexures, etc.
  - d. The Terms and Conditions of the Contract
  - e. The Schedule of Requirement

- f. The Technical Specification
  - g. Any other document listed in the supplier's bid and replies to queries, clarifications issued by the purchaser, such confirmations given by the bidder which are acceptable to the purchaser and the entire Addendum issued as forming part of the Contract.
3. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide, the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract. .
  4. The purchaser hereby covenants to pay the Supplier in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

Brief particulars of the goods and services which shall be supplied / provided by the Supplier are as under:

S.No.	Drug Code	Name of Product	UNIT	Tender Qty in Unit*  (A)	Unit Price ( in Rs.)exclusive of ED,CST/VAT  (B)	Total value exclusive CST/VAT (A x B)
<b>Total Contract Value</b>						

- \* **Tender quantity indicated here is tentative and may vary subjected to various terms and conditions of the tender.**
- \* **Excise duty as applicable on MRP and MRP to be intimated by BPPI at the time of placing orders will be payable as per prevailing excise duty rates.**

## **DELIVERY SCHEDULE**

Supply shall all complete within 50th day from the date of issue of Ist purchase order and within 40<sup>th</sup> day from the date of issue of subsequent purchase order.

## **Dispute Resolution**

This agreement shall be deemed to have been made/ executed at Delhi for all purpose.

Normally, there should not be any scope of dispute between the BPPI and the \_\_\_\_\_ after entering into a mutually agreed valid contract/agreement.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/agreement leading to disagreement BPPI and the \_\_\_\_\_ shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the \_\_\_\_\_ shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be full and final which shall be binding on both the parties.

## **Governing Law/Jurisdiction**

The applicable law governing this agreement shall be the laws of India and the court of Delhi shall have the exclusive jurisdiction to try any dispute arising out of the violation of any terms and condition of this agreement.

IN WITNESS where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered by the

Said.....(For the Purchaser)

Name –

Address- IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

Designation -

In the presence of witness.....

Signature

Name

Address- IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016  
(Haryana)

Designation – Executive (Procurement)

Signed, Sealed and Delivered by the

Said.....(For the Supplier)

Name

Address

Designation

In the presence of witness .....

Signature

Name

Address Designation



**ANNEXURE -XIV**

Ref. Clause no 13

**DECLARATION**

I/We do hereby declare that I/we will supply the drug as per the design in enclosures to this Annexure as well as other instruction given in this regard.

Signature of the Tenderer

Name

Designation

(Company Seal)

**ANNEXURE –XIV(A)**

Ref. Clause No. 13

**UNDERTAKING**

I / we do hereby declared that I/we will supply the drugs by affixing logo on Primary/Secondary/ Tertiary packing for the imported items along with the generic name as per the designs given in enclosures to this annexure as well as other instructions given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

**Enclosure–1 to ANNEXURE -XIV AND XIVA)**

**Ref. Clause No. 13**

**DESIGN FOR: Foil / blister of tablet and capsule**

1. **Text Matter Printing on Foil /Blister** should be in minimum two colour i.e. Black & red. **However, colour and design of PMBJP(Pradhan Mantri Bhartiya Janaushadhi Pariyojana) logogram in standard colour from at as per approval at the time of ART WORK approval before supply should be as given below.**
2. PMBJP Logogram should be placed along with the address as given below
3. BPPI helpline number 1800 180 8080 should be printed
4. Font type should in CALIBIRI format for any type of title name of generic medicines
5. Title name of generic medicine should be **bold** in minimum 12 font size and it may increase respectively according to size of label & the rest text matter should be minimum in.
6. The stereo printing of batch no./manufacturing /expiry date & other details shouldn't overlap the text matter.
7. "Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex, Dundahera , Gurgaon 122016 (Haryana)

BPPI helpline number 1800 180 8080

Or

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

BPPI helpline number 1800 180 8080

1. Pradhan Mantri Bhartiya Janaushadhi Pariyojana should be printed in Hindi at side of strips.

**Enclosure – 2 to ANNEXURE –XIV & ANNEXURE –XIV(A)**

**Ref. Clause No. 13**

**1. Design for injection for primary packing**

- a) Vial (5ml or more) should be supplied with the following PMBJP logogram **as per approval at the time of ART WORK approval before supply** as under:
- b) BPPI helpline number 1800 180 8080 should be printed
- c) Font type should in CALIBIRI format for any type of title name of generic medicines
- d) Title name of generic medicine should be minimum 12 font size and it may increase respectively according to size of label.
- e) “Bureau of Pharma PSUs of India” should be running text only and should not be prominent.



Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

BPPI helpline number 1800 180 8080

**b) Ampoules or Vials less than 5 ml for primary packing**

- (i) Injection in ampoule or vial (less than 5 ml) should be supplied with PMBJP logogram **as per approval at the time of ART WORK approval before supply** as under (colour should be black)
- (ii) BPPI helpline number 1800 180 8080 should be printed
- (iii) Font type should in CALIBIRI format for any type of title name of generic medicines
- (iv) Title name of generic medicine should be minimum 12 font size and it may increase respectively according to size of label.
- (v) “Bureau of Pharma PSUs of India” should be running text only and should not be prominent.

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

BPPI helpline number 1800 180 8080

(vi) **LIQUID:**

- a) Liquid preparation should be supplied with pilfer proof ROPP cap.
- b) Bottle cap should not bear the manufacturer's logogram
- c) Bottle label should bear PMBJP logogram **as per approval at the time of ART WORK approval before supply** as below:
- d) BPPI helpline number 1800 180 8080 should be printed
- e) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent
- f) Font type should be in CALIBIRI format for any type of title name of generic medicines
- g) Title name of generic medicine should be minimum 12 font size and it may increase respectively according to size of label.



Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

BPPI helpline number 1800 180 8080

### 3. OINTMENTS / CREAMS

- a) Ointment / Cream /Gel /Glass Jar should bear JANASHADHI or PMJAY logogram **as per approval at the time of ART WORK approval before supply** as below:

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex, Dundahera , Gurgaon 122016 (Haryana)

BPPI helpline number 1800 180 8080

- b) BPPI helpline number 1800 180 8080 should be printed
- c) Ointment / cream tube should be packed in mono carton (secondary packing) with PMBJP logogram **as per approval at the time of ART WORK approval before supply** as given below.
- d) “Bureau of Pharma PSUs of India” should be running text only and should not be prominent
- e) Font type should in CALIBIRI format for any type of title name of generic medicines
- f) Title name of generic medicine should be minimum 12 font size and it may increase respectively according to size of label.

**Enclosure 3 to ANNEXURE –XIV(A)**

**SPECIMEN LABEL FOR MONO CARTON (Secondary Packing)**

Rx  
Tablets

10 X 10's

Generic Name of Product



Manufactured for :

Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

BPPI helpline number 1800 180 8080

For Ampoules/vials :- All secondary packing box/carton should be supplied with printed text matter as per guidelines.

Note: An additional to statutory requirement under Drug & Cosmetic Act 1940 and rules 1945

## ANNEXURE-XV

Ref. Clause No.14.1

### SCHEDULE FOR PACKAGING OF DRUGS

#### GENERAL SPECIFICATIONS

1. Strips of Aluminum foils should be gauge 04.
2. Aluminum foils s back material for blisters should be gauge 025.
3. The rigid PVC used in blister packing should be of not less than 250 micron
4. All glass bottles should be new neutral glass. Pet bottles so accepted as per drug laws stipulation.
5. Ointments should be packed in lacquerized Aluminum Tubes or Lami tubes.
6. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
7. Specification of outer cartons are as given in this Schedule .
8. In case of any conflict between Carton specifications and packets per carton specification the specification of the packets / carton shall prevail.
9. All plastic containers should be made of virgin grade plastics
10. Injection in vials should have a flip-off seals.
11. The strips shall be aluminum strip / blisters with aluminum foil back.
12. The minimum diameters of each tablets should be of 6.4mm
13. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM(**off white/grey is not acceptable**). **The material to be used for carton should be from virgin chemical pulp.**
14. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle.
15. All primary/secondary/tertiary packaging should have JA/PMJAY logo.
16. Two Horizontal/vertical/standing lines in two different colour will be there on Primary and secondary packaging, so as to differentiate therapy groups. The colours of lines will be intimated during Artwork approval.



17. The primary packing should be decided by the party depending on the drug category as per D&C act. For e.g if drug is hygroscopic then tablet should be packed in Alu/Alu blister or if it is light sensitive then to be packed in Amber colour PVC e.t.c.

**(Schedule)**

1.	<b>CORRUGATED BOXES(Liquid)</b>
	1. No corrugate package should weigh more than 15 kgs (i.e. product + inner carton + corrugated box).
	2. All Corrugated boxes should be of 'A' grade paper i.e. Virgin and 7 Ply.
	3. All items should be packed only in first hand boxes only.
2.	<b>FLUTE</b>
	The corrugated boxes should be of narrow flute.
3.	<b>JOINT</b>
	Every box should be preferably single joint and not more than two joints.
4.	<b>STITCHING</b>
	Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.
5.	<b>FLAP</b>
	The flaps should uniformly meet but should not over lap each other. The flap when turned by 45 - 60° should not crack.
6.	<b>TAPE</b>
	Every box should be sealed with gum tape running along the top and lower opening.
7.	<b>CARRYSTRAP:</b>
	Every box should be strapped with two parallel nylon carry straps (they should intersect).
8.	<b>LABEL</b>
	The product label on the carton should be large at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength of the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.
9.	<b>OTHERS</b>
	No box should contain mixed products or mixed batches of the same product.

**II. SPECIFICATION OF CORRUGATED BOXES HOLDING TABLETS / CAPSULES / PESSARIES**

(1) The box should not weigh more than 7-8 kgs. The grammage of outer box should be 150 gsm and inside partition / lining should be 120 gsm.

(2) The box should be of 7 ply with bursting strength of 9 Kg / Cm<sup>2</sup>

**III. SPECIFICATIONS OF CORRUGATED BOXES FOR OINTMENT / CREAM / GELS PACKED IN TUBES:**

- (1) No corrugate box should weigh more than 7-8 Kgs.
- (2) Every Ointment tube should be individually packed in carton and then packed in 20's in a white board box, which may be packed in a corrugated box.
- (3) Grammage:  
Outer box should be 150 gsm inside partition /  
Lining should be 120gsm.

#### IV. SPECIFICATIONS OF CORRUGATED BOXESFOR INJECTABLE (IN VIALS AND AMPOULES)

- (1) Vials may be packed in corrugated boxes weighing up to 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 kgs.
- (2) C.B. for vials should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply, while C.B. for ampoules should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply.
- (3) Bursting strength for CB boxes for
  - i. Vials : Note less than 13 Kg/Cm<sup>2</sup>
  - ii. Amp : Note less than 9 Kg/Cm<sup>2</sup>
- (4) In the case of 10 ml Ampoules 100 or 50 ampoules may be packed in a grey board box. Multiples of white board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.
- (5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with centre pad.
- (6) In case of ampoules every white board box should carry 5 amps. Cutters placed in a polythene bag.
- (7) Vials of eye, ear drops and nasal drops should be packed in an individual carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a white board box.

**ANNEXURE -XVI**

**MANDATE FORM**

Ref. clause 16.2

Sl.No.	Details Required	
1.	<b>Company Name</b>	
	PAN Number	
	TIN Number	
	Date of Inception	
	Licence No. & Date	
	Issued By	
	Valid Upto	
2.	Postal Address of the Company	
	Telephone No.	
	Fax No.	
	E-mail ID	
	Alternate E-mail ID	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No	
	E-mail ID	
4.	Name and Designation of the authorized company official	Name: Designation:
	Mobile No.	
	E-mail ID	
5.	<b>Bank Details</b>	
	a) Name of the Bank	
	b) Branch Name & address	
	c) Branch Code No.	
	d) Branch Manager Mobile No.	
	e) Branch Telephone no	
	f) Branch E-mail ID	
	g) 9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank	
	h) IFSC Code of the Branch	
	i) Type of Account (Current / Savings)	
	j) Account Number (as appear in cheque book)	

(In lieu of the bank certificate to be obtained, please **upload the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold Bureau of Pharma Public Sector Undertakings of India (BPPI) responsible. I have read the conditions of the tender / agreement entered and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date:	Company Seal	Signature
Place:	(Name of the person signing & designation)	

---

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:

-----  
---